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Relief from pain is a major goal of all branches of medicine, and poorly 
controlled pain is associated with substantial economic and human burden. Mu opioid 
receptors are targets for strong pain relief, mediating the analgesia of widely used 
analgesic drugs like morphine, hydrocodone, oxycodone, methadone, and fentanyl. 
Unfortunately, these drugs are associated with numerous side effects such as 
constipation, respiratory depression, physical dependence, abuse, and addiction. 
 The mu opioid receptor gene undergoes extensive alternative splicing, although 
the physiological relevance of many of these splice variants is only now becoming clear. 
In particular, some of these splice variants produce truncated receptors possessing only 
6 transmembrane domains, short of the canonical 7 transmembrane domain structure 
conserved across the G-protein coupled receptor superfamily. Initial studies suggested 
that these receptors were expressed in low levels relative to full length variants, and 
could not bind mu agonist drugs when they were transiently expressed in cell lines, 
calling into question their importance in opioid receptor pharmacology. 
 Here, we show that these truncated receptors are in fact targets for a new pain 
reliever, IBNtxA, which is a potent pain reliever in mice and rats, yet exhibits a 
dramatically improved side effect profile over current clinically-used mu analgesics. 
IBNtxA shows only mild constipation, does not depress respiration or produce physical 
dependence, and shows neither rewarding nor aversive behavior in a conditioned place 
preference assay. We also examined the pharmacology and regional distribution of this 
target in rat brain using a radioiodinated form of the drug. Photoaffinity labels based on 
  
 
the structure of IBNtxA were also synthesized and characterized, and we present 
evidence consistent with the labeling of truncated mu opioid receptor splice variants in 
mouse brain. 
 Other pain relievers were also found to require these truncated receptors for 
their analgesic effects, such as the clinically used opioid buprenorphine, as well as 
kappa1 agonists and clinically used alpha2 agonists. Importantly, dose- or use-limiting 
side effects for each of these drugs were found to be present in knockout animals 
lacking the truncated splice variant isoforms, suggesting that the desired analgesic 
properties can be separated from their unwanted side effects. 
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Chapter 1: Introduction 
“No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because 
those who do not know how to pursue pleasure rationally encounter consequences that 
are extremely painful. Nor again is there anyone who loves or pursues or desires to 
obtain pain of itself, because it is pain, but because occasionally circumstances occur in 
which toil and pain can procure him some great pleasure.” 
      Cicero, On the Ends of Good and Evil, 45 BC 
 
Pain is an evolutionarily essential behavior. Nociceptive signals maximize the fitness of 
the individual, disincentivizing actions that result in physical harm and thus endanger 
the individual’s chances of reproductive success. In humans, congenital insensitivity to 
pain is associated with substantially increased risk of self-injury and subsequent 
infection, frequently resulting in mortality in childhood (Nagasako et al., 2003). 
However, in a situation of imminent danger, such as an encounter with a predator, near-
term survival outweighs the long-term fitness value of avoiding tissue damage. Thus, the 
endogenous opioid system appears to have evolved to silence painful stimuli, facilitating 
“fight or flight” via fear-induced hypoalgesic response (Fanselow, 1986). 
It is not surprising, then, that the amelioration of pain should be physiologically 
associated with reward. Indeed, opiates were likely among the first euphoriant drugs: 
Papaver somniferum was cultivated in Mesopotamia around 3400 BCE in what is now 
Iraq (Brownstein, 1993). Ancient Sumerians harvested opium from these seed pods, 
which they called hul gil or “the plant of joy.” Although the many medical uses of opium 
were also appreciated many thousands of years ago in the earliest known medical text, 
the Ebers Papyrus (ca. 1550 BCE), the pharmaceutical and rewarding aspects of the drug 
have always existed side by side. 
As powerful pain relievers, opioid drugs such as morphine, fentanyl, and 
oxycodone are widely used clinically. Due to their long history and proven efficacy, 
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these mu opioids are the mainstay in the management of moderate to severe acute and 
chronic pain, but many patients report inadequate pain control (Moskovitz et al., 2011). 
In many, side effects such as constipation, nausea and vomiting, sedation, and potential 
for abuse result in suboptimal dosing or even discontinuation of treatment, and millions 
of patients suffer poorly controlled pain at substantial human and economic cost 
estimated at hundreds of billions of dollars annually (Institute of Medicine, 2011). Not 
surprisingly, major depression, post-traumatic stress disorder, and anxiety disorders are 
significantly more prevalent in patients with chronic pain according to the National 
Comorbidity Study (McWilliams, Cox, & Enns, 2003). Furthermore, patients with chronic 
pain frequently report suicidal ideation (Racine, Choinière, & Nielson, 2014) and are 
twice as likely as patients without chronic pain to commit suicide (Tang & Crane, 2006). 
 Clearly, then, there is a significant unmet need for strong analgesic drugs with 
improved side effect profiles (Moskovitz et al., 2011). Thousands of synthetic opioid 
compounds have failed to supplant morphine as the “gold standard” for the treatment 
of severe pain, although studies have failed to show its superiority over other mu 
opioids (Gálvez & Pérez, 2012). However, decades of research have repeatedly 
demonstrated the heterogeneity of opioid receptor targets. Further elucidation of this 
concept of receptor multiplicity will facilitate the development of a new generation of 
opioid drugs that offer the benefits of powerful pain relief with fewer adverse effects. 
Opioid Receptors 
 The history of opioid receptor pharmacology is inextricably tied to the history of 
the radioligand binding assay. Although physiologists such as Langley, Hill, and Ehrlich 
conceived of “receptors” which bound and mediated the actions of drugs in the early 
1900s (Rang, 2006), no such neurotransmitter receptor had ever been concretely 
demonstrated until 1970. Changeux et al (Changeux, Kasai, & Lee, 1970) used a tritium-
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labeled acetylcholine receptor ligand, decamethonium, to probe protein extracted from 
the receptor-rich electric organ of the Torpedo ray. Previously, it had been impossible to 
differentiate the acetylcholine receptor binding from the enzyme acetylcholinesterase 
(AChE) binding as the available radioligands exhibited high affinity for both proteins. 
Changeux used a recently-isolated component of snake venom called alpha-
bungarotoxin which bound acetylcholine receptors but not AChE, allowing him to 
definitively identify specific receptor binding versus nonspecific interaction of the 
radioligand with other macromolecules such as enzymes. 
Still, the discovery that acetylcholine receptors made up nearly 20% of the 
weight of the peculiar Torpedo ray electric organ led many researchers to doubt that 
neurotransmitter receptors, expressed at dramatically lower abundance in the brain, 
would be discovered in their lifetimes (Snyder, 2009). Pioneering pharmacologist Avram 
Goldstein attempted to use the opiate levorphanol and its inactive enantiomer to 
demonstrate the existence of a stereoselective receptor for opiates, but was limited by 
low specific activity of the tritiated levorphanol radioligand (Goldstein, Lowney, & Pal, 
1971). However, Goldstein’s idea that the criteria of stereoselectivity could be used to 
determine that observed binding corresponded to the receptor mediating a drug’s 
physiological effects would later prove crucial. 
Outside of the CNS, Cuatrecasas had been able to successfully use 125I-labeled 
insulin to discover the insulin receptor in fat cells (Cuatrecasas, 1971), and Lefkowitz 
discovered 125I-labeled ACTH binding in the adrenal gland (Lefkowitz, Roth, Pricer, & 
Pastan, 1970). Finally in 1973, the labs of Sol Snyder andd Lars Terenius, and shortly 
thereafter Eric Simon used tritiated naloxone, dihydromorphine, or etorphine, 
respectively, to demonstrate the existence in the mammalian brain of an opiate 
receptor (C. B. Pert & Snyder, 1973; Simon, Hiller, & Edelman, 1973; Terenius, 1973). 
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Importantly, while the biologically active (-)-enantiomers of methadone, levallorphan, 
and levorphanol competed this binding with very high affinity, the inactive (+)-
enantiomers exhibited dramatically lower affinity for the site, confirming its identity as 
the target mediating the physiological effects of opioid drugs. 
Opioid Receptor Multiplicity 
The first demonstrations of a receptor in the central nervous system for opiates 
naturally inspired far more questions than they answered. What were brain’s 
endogenous opiate ligands? Where were opiate receptors expressed and how did they 
mediate their effects? Finally, were there other opiate receptors? 
Earlier, clinical studies revealed that low doses of nalorphine antagonized 
morphine analgesia, but higher doses analgesia returned, which was most easily 
explained by the existence of multiple opioid receptors (Houde & Wallenstein, 1956; 
Lasagna & Beecher, 1954). Portoghese had further speculated that as nalorphine was 
only able to reverse some of the effects of certain Diels-Alder adducts1 of thebaine 
(Bentley et al., 1965), “it seems likely that there may be several different species of 
narcotic analgesic receptors” (Portoghese, 1965, p609).  
Shortly thereafter, Martin proposed the existence of “M” and “N” receptors (for 
morphine and nalorphine) to explain the differences between the effects of various 
opioid drugs, a concept he called “receptor dualism” (Martin, 1967). After the 
demonstration of opioid receptors in 1973, Martin et al categorically investigated the 
effects of different opioid compounds such as morphine, buprenorphine, n-allyl-
normetazocine (SKF-10,047), and ketocyclazocine, in the chronic spinal dog (Gilbert & 
                                                      
1 These resulting endo-theno derivatives, known as orvinols and thevinols, include the extremely potent 
agonist etorphine, mu partial-agonist/kappa antagonist buprenorphine, and mu/delta/kappa antagonist 
diprenorphine, all of which exhibit very high affinity for opioid receptors but little or no selectivity for any 
one class of receptor. 
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Martin, 1976; Martin, Eades, Thompson, Huppler, & Gilbert, 1976). Importantly, they 
discovered that ketocyclazocine, despite behaving as an analgesic and suppressing the 
flexor reflex as well as constricting pupils like morphine, did not alter body temperature 
and only weakly affected pulse and respiratory rate. Furthermore, ketocyclazocine 
neither strongly precipitated nor ameliorated a withdrawal syndrome in morphine-
tolerant animals. On the basis of these studies, Martin proposed the existence of at 
least 3 opioid receptors, and named them mu (for morphine), kappa (for 
ketocyclazocine), and sigma (for SKF-10,047). Indeed, we now know that the Bentley 
compound to which Portoghese was referring, M320, is a full kappa agonist like 
ketocyclazocine, explaining why its analgesia could not be reversed by the mu 
antagonist/kappa agonist nalorphine (Lewis, 1999). We also now know that sigma 
receptors are not in fact opioid at all, although they modulate the effects of opioid 
analgesia by altering their interactions with G-proteins (Kim et al., 2010). 
Hans Kosterlitz had previously championed2 the use of isolated tissue 
preparations such as guinea pig ileum and mouse vas deferens to measure the potency 
and efficacy of opioids in vitro ((Gyang, Kosterlitz, & Lees, 1964; Henderson, Hughes, & 
Kosterlitz, 1972; Kosterlitz & Robinson, 1955, 1957, 1958). His young protégé, John 
Hughes, had been the first to sequence the endogenous opioid peptides leu- and met-
enkephalin (Hughes and Kosterlitz, 1975), his success in no small part due to these in 
vitro assays. Together, the laboratory of Hughes and Kosterlitz would also be the first to 
demonstrate the existence of multiple opioid receptors in vitro, showing that guinea pig 
ileum primarily contained mu-like receptors, while the mouse vas deferens contained 
                                                      
2 Notably, the first demonstration of the effect of morphine on the peristaltic action of the isolated guinea 
pig ileum long predated Kosterlitz. Pioneering German pharmacologist Paul Trendelenburg first reported 
the qualitative effects of various drugs on this reflex in a seminal 1917 paper. Paton (1956), alongside 
Kosterlitz and Schaumann (1955), developed Trendelenburg’s findings into an effective assay which would 
permit quantitative in vitro comparisons between new opioid derivatives on the basis of their potency and 
efficacy (Gyang, Kosterlitz, and Lees 1964; recounted in Lees 1998). 
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another population, named delta (for vas deferens) which differed in its selectivity from 
Martin’s kappa receptor (Lord, Waterfield, Hughes, & Kosterlitz, 1977). 
Opioid Receptor Multiplicity: Mu Subtypes 
The discovery of multiple opioid receptors failed at first to achieve the holy grail 
of opiate research – that is, the discovery of a powerful pain reliever lacking the side 
effects of morphine such as constipation, respiratory depression, and abuse potential. 
Although full agonists of kappa receptors such as nalorphine and ketocyclazocine were 
tested in humans as analgesics, they produced psychotomimesis and dysphoria in 
patients and their use was not further pursued for this indication (Cahal, 1957; Kumor, 
Haertzen, Johnson, Kocher, & Jasinski, 1986). Lower efficacy agonists at kappa receptors 
such as pentazocine, a mixed kappa agonist/mu antagonist, were approved with the 
caveat that higher doses could cause these undesirable side effects; they continue to be 
used today, albeit rarely, with prescriptions vastly exceeded by those of mu opioid 
agonists such as morphine, hydrocodone, oxycodone, and fentanyl. 
 Importantly, although drugs could be grouped into mu, delta, kappa or sigma 
families, in was clear that not all mu agonists were interchangeable. Clinically, physicians 
have long appreciated the differences between mu analgesic drugs, within and between 
patients, and tailored therapy accordingly to minimize side effects such as nausea seen 
with one drug but not with another (G. W. Pasternak & Pan, 2013). Furthermore, the 
phenomenon of incomplete cross-tolerance is observed clinically between mu 
analgesics, permitting the practice of “opioid rotation,” whereby a patient highly 
tolerant to one drug may be switched to another at a lower dose than would be 
predicted based solely on potency ratios (Cherny et al., 2001). By lowering the dose 
required to control a patient’s pain, opioid rotation often achieves a reduction in the 
side effects accompanying the higher doses of the patients’ former opioid. Clearly, these 
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clinical observations support a more complex model than single, homogeneous 
population of receptors mediating mu opioids’ analgesic effects. 
 The first experimental evidence in favor of multiple “mu” subtypes came from 
investigations with the naloxone-derivative naloxazone. Naloxazone inhibition of 
binding was found to be very long lasting and resistant to repeated washes - binding 
was functionally irreversible, unlike the parent compound which behaved as a 
traditional reversible competitive antagonist (G. W. Pasternak & Hahn, 1980). Consistent 
with in vitro findings, pretreatment of mice with a single dose of naloxazone 
dramatically shifted the ED50 of morphine 11-fold a full day later, unlike naloxone (G. W. 
Pasternak, Childers, & Snyder, 1980). Surprisingly, despite this loss of analgesia, there 
was no significant difference in the LD50 of morphine, suggesting that the binding of 
naloxazone to the receptors mediating respiratory depression was rapidly reversible, 
whereas the blockade of the sites mediating analgesia was very long lived.  Naloxone 
administered to naloxazone-pretreated animals immediately before a lethal dose of 
morphine prevented death, confirming the opioid nature of the effect. The brains of 
naloxazone-pretreated animals exhibited wash-resistant loss of a high affinity site (0.8 
nM) comprising about 10% of total [3H]-naloxone binding, while the remaining lower 
affinity binding (2.3nM) was unaffected.  
A short time later, the observed effects of naloxazone were found to be 
mediated in earnest by naloxonazine, a stable dimer of the parent azone compound 
spontaneously formed under acidic conditions (Hahn, Carroll-Buatti, & Pasternak, 1982; 
Hahn & Pasternak, 1982). Naloxonazine pretreatment perfectly recapitulated the results 
obtained with naloxazone, but at doses 20-fold lower (Ling, Simantov, Clark, & 
Pasternak, 1986). The high affinity binding site associated with morphine analgesia was 
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named the mu1 subtype, while the moderate affinity site associated with respiratory 
depression was named mu2. 
 Further studies on mu subtypes revealed that naloxonazine could dissociate 
morphine analgesia not only from respiratory depression (Ling, Spiegel, Lockhart, & 
Pasternak, 1985; Ling, Spiegel, Nishimura, & Pasternak, 1983), but also physical 
dependence (Ling, MacLeod, Lee, Lockhart, & Pasternak, 1984). Despite loss of analgesia 
in naloxonazine pre-treated rats, animals continuously infused with I.V. morphine 
continued to express profound withdrawal signs when given a challenge dose of 
naloxone, suggesting that morphine analgesia and physical dependence were not 
mediated by the same population of receptors. 
 These studies also revealed a difference in receptor distribution; both mu1 and 
mu2 sites were found supraspinally, while only mu2 sites were present in the spinal cord  
 (G. W. Pasternak et al., 1983; Paul, Bodnar, Gistrak, & Pasternak, 1989). Further studies 
identified mu2 sites in the gut which mediate the peripheral component of morphine’s 
constipating effects (Gintzler & Pasternak, 1983; Heyman, Williams, Burks, Mosberg, & 
Porreca, 1988; Paul & Pasternak, 1988). Finally, the spontaneously-occurring mu-
deficient CXBK mouse strain was found to have no difference from wildtype animals in 
the analgesic potency of intrathecal morphine, but a >20-fold shift in i.c.v. morphine 
(Figure 1; Pick, Nejat, & Pasternak, 1993). The authors further observed that morphine 
 given i.c.v. potentiated a fixed dose of morphine given intrathecally, a synergy that was 
poorly blocked by the mu1 antagonist naloxonazine at doses that readily blocked i.c.v. 
morphine alone – implicating a mu2-dependent mechanism for supraspinal/spinal 
synergy. Consistent with these results, CXBK animals exhibited nearly identical 
supraspinal/spinal synergy to wildtype controls, despite profound loss of analgesia to 
i.c.v. morphine alone.  
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Opioid Receptor Multiplicity: Kappa Subtypes 
 Like mu receptors, kappa receptors could also be subdivided based on receptor 
binding. For many decades, benzomorphans such as 3H-ethylketocyclazocine (a 
derivative of the prototypical agonist, ketocyclazocine) and 3H-bremazocine were used 
to study kappa receptor binding, despite the fact that they were not very selective for 
kappa receptors. Studies looking at kappa binding therefore used tissues which were 
enriched for kappa receptors and deficient in mu and delta receptors, such as the 
guinea pig cerebellum and lumbo-sacral spinal cord, or used mu and delta selective 
blockers to artificially enrich for the desired kappa sites. In the guinea pig lumbo-sacral 
spinal cord, 3H-bremazocine labeled both classical kappa sites as well as “benzomorphan 
 
 
Figure 1: Effect of morphine on CD-1 and CXBK mice. 
(Left) i.c.v morphine analgesia is lost while i.t. morphine is intact in the spontaneously 
mu-deficient CXBK mice, suggesting distinct receptor mechanisms for spinal and 
supraspinal morphine analgesia. (Right) Despite near-total loss of supraspinal morphine 
analgesia, there is no difference in the ability of i.t. morphine to potentiate i.c.v. 
morphine analgesia relative to wildtype CD-1 controls. Reproduced from (Pick et al., 
1993). 
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sites,” termed kappa2 (Attali, Gouardères, Mazarguil, Audigier, & Cros, 1982a, 1982b). 
These sites could also be observed in guinea pig striatum using 3H-etorphine in the 
presence of mu- and delta-selective blockers, further supporting a distinction between 
subtypes (Audigier, Attali, Mazarguil, & Cros, 1982; Gouarderes, Attali, Audigier, & Cros, 
1983). The synthesis of the non-benzomorphan kappa-selective small molecule U50,488 
(Szmuszkovicz & Von Voigtlander, 1982; Vonvoigtlander, Lahti, & Ludens, 1983) and 
subsequent resolution of its enantiomers (DeCosta, George, Rothman, Jacobson, & Rice, 
1987) dramatically simplified the differentiation between kappa sites, as kappa1 binding 
was U50,488-sensitive while kappa2 binding was U50,488-insensitive (Rothman et al., 
1989; Zukin, Eghbali, Olive, Unterwald, & Tempel, 1988). Still, the whether all of these 
studies were measuring the same kappa sites is unclear given the different tissues and 
radioligands used to define the binding. 
 Competition studies further fragmented kappa binding, as Clark et al (1989) 
demonstrated that even kappa1 sites were not a homogeneous population. Despite 
monophasic competitions by kappa ligands such as U50,488, tifluadom, Mr2034, and 
the endogenous kappa peptide Dynorphin A (1-17), both 3H-ethylketocyclazocine and 
3H-U69,593 binding in guinea pig cerebellum was clearly biphasic when competed by 
the endogenous peptides Dynorphin B and alpha-neoendorphin, leading the authors to 
declare the existence of kappa1a and kappa1b sites (Clark et al., 1989). In the same paper, 
Clark et al demonstrated yet another site, named Kappa3, which was bound reversibly 
by a new naloxone derivative, 3H-naloxone benzoylhydrazone (NalBzoH).  The 
classification of this site as a kappa receptor subtype was justified by high affinity for the 
prototypical kappa ligand, ketocyclazocine, as well as a number of other kappa drugs 
such as Mr2034 and WIN44,441, yet it was insensitive to the kappa1-selective agonist 
U50,488 and antagonist norBNI. Binding also clearly differed from the previously 
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described kappa2 sites as kappa3 binding was competed with high affinity by 
ethylketocyclazocine and tifluadom.  
 Behavioral studies supported the preliminary characterization of a separate 
kappa3 site labeled by NalBzoH. Although its binding was nonselective, at low doses it 
antagonized both mu1 and mu2 analgesia independently of one another, which was 
shown by blocking i.c.v. or i.t. DAMGO analgesia (Gistrak, Paul, Hahn, & Pasternak, 
1989). Consistent with its characterization as a mu antagonist, NalBzoH also prevented 
morphine lethality and constipation. It also antagonized delta analgesia produced by i.t. 
DPDPE as well as kappa1 analgesia produced by s.c. U50,488. As with nalorphine years 
earlier, though, at higher doses, NalBzoH was itself analgesic, and animals were not 
cross-tolerant with either morphine or U50,488 – reinforcing the conclusion that kappa3 
receptors could be an important target for powerful pain relief with mitigated side 
effects.  
Evidence for a distinct kappa3 receptor was bolstered further by re-examination 
of the behavioral pharmacology of mixed agonist-antagonist drugs nalorphine and 
nalbuphine which had been around for decades. Indeed, nalorphine’s differing actions 
in the chronic spinal dog had been the original basis for Martin’s proposal of a distinct 
“N” opioid receptor in addition to an “M” receptor that mediated the effects of 
morphine (Martin, 1967). Nalorphine had since been classified as a mu 
antagonist/kappa agonist, yet new studies found its analgesia to be insensitive to the 
kappa1 antagonist norBNI (Paul, Pick, Tive, & Pasternak, 1991). Furthermore, animals 
made tolerant to nalorphine were not cross-tolerant to morphine or U50,488, while 
they were cross-tolerant with naloxone benzoylhydrazone. Finally, animals made 
tolerant to U50,488 were not cross-tolerant with nalorphine – strong evidence that the 
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target mediating its analgesia was not the kappa1 receptor but rather the newly 
discovered kappa3 receptor. 
Nalbuphine, another drug classified as a mu antagonist/kappa agonist, was also 
found to interact with kappa3 receptors supraspinally in vivo, although analgesia was 
readily reversed reversed by i.t. norBNI, consistent with kappa1-dependent analgesia at 
the spinal level (Pick, Paul, & Pasternak, 1992). U50,488 and nalbuphine analgesia was 
synergistic, rather than additive, supporting this interpretation. Finally crosstolerance 
between nalbuphine and U50,488 was unidirectional, with U50,488-tolerant animals 
showing tolerance to nalbuphine, but not the reverse; however, animals were 
bidirectionally crosstolerant to the kappa3 agonists NalBzoH and  nalorphine, reinforcing 
the partial role for kappa3 receptors in nalbuphine’s actions. 
Cloning of the Opioid Receptors 
 The advent of molecular biology techniques ushered in a new era of opioid 
pharmacology. Kieffer et al and Evans et al independently cloned the first (delta) opioid 
receptor by screening cDNA libraries created from NG108-15 cells (Evans, Keith, 
Morrison, Magendzo, & Edwards, 1992; Kieffer, Befort, Gaveriaux-Ruff, & Hirth, 1992). 
This cell line, produced by fusion of mouse NG18TG2 neuroblastoma and rat C6 glioma 
cells, natively expresses delta opioid receptors and had been used to great effect as the 
first in vitro preparation of opioid receptors derived from cell culture (Klee & Nirenberg, 
1974), leading to the discoveries that opioid receptors are negatively coupled to 
adenylate cyclase activity (Sharma, Nirenberg, & Klee, 1975) and that adaptations in 
cAMP regulation in response to chronic opioid treatment could explain phenomena such 
as tolerance and dependence (Sharma, Klee, & Nirenberg, 1975). These hybrid cells 
would further prove essential in establishing the actions of the delta opioid receptor as 
guanosine nucleotide-dependent (Koski & Klee, 1981; Sharma, Klee, & Nirenberg, 1977) 
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and mediated by a pertussis-toxin sensitive member of the G-protein family (Burns, 
Hewlett, Moss, & Vaughan, 1983; Hsia, Moss, Hewlett, & Vaughan, 1984; Kurose, 
Katada, Amano, & Ui, 1983). 
After transfection of COS cells with fractions of the cDNA library, Kieffer et al 
used binding by the delta-selective enkephalin derivative [3H]-DTLET to screen for 
positive pools of cells which were then fractionated recursively until a single clone was 
isolated. Evans et al transfected COS cells with the entire library, then screened colonies 
by autoradiography with another enkephalin derivative, [125I]-DADLE – which, although 
not selective for delta receptors owing to its affinity for mu1 sites (Nishimura, Recht, & 
Pasternak, 1984), had the benefit of dramatically higher specific activity of 125I rather 
than 3H. Unsurprisingly, both Kieffer and Evans discovered the same cDNA which 
conferred delta peptide binding activity to transfected cell membranes with a selectivity 
profile consistent with delta sites. 
Shortly after this discovery, Chen et al used the mouse DOR-1 cDNA to probe a 
rat cDNA library with low hybridization stringency; the researchers isolated a cDNA 
which conferred on COS cells [3H]-diprenorphine binding competed with nanomolar 
affinity by the highly mu-selective enkephalin derivative, DAMGO (Chen, Mestek, Liu, 
Hurley, & Yu, 1993).  Binding was also competed with high affinity by mu-selective small 
molecules such as naloxonazine, b-funaltrexamine, and cyprodime, while the delta-
selective peptides DPDPE and DSLET and kappa-selective small molecule U50,488 had 
dramatically lower affinity. Finally, the authors demonstrated that the receptor was 
negatively coupled to adenylate cyclase, confirming that it was a member of the G-
protein coupled receptor family as expected of the true mu opioid receptor. A number 
of other labs independently reported sequences of the mu receptor in the ensuing  
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months (Fukuda, Kato, Mori, Nishi, & Takeshima, 1993; R. C. Thompson, Mansour, Akil, 
& Watson, 1993; Wang et al., 1993). 
Kappa opioid receptors were cloned serendipitously by Yasuda et al, who were 
screening a mouse cDNA library with probes for the somatostatin receptor family 
(Yasuda et al., 1993). Two clones were isolated with approximately 61% sequence 
Figure 2: Serpentine model of the rat MOR-1 amino acid sequence and opioid family 
homology.  
Residues are denoted by their 1-letter code, with Roman numerals denoting 
transmembrane domains and intra/extracellular loops. Residues highly conserved 
across the rhodopsin-like class A GPCR subfamily are shown in black, while residues 
conserved across mu, delta, and kappa receptors are shown in gray. Reproduced from 
(Subramanian, Paterlini, Portoghese, & Ferguson, 2000). 
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identity to one another and 35% sequence identity to the somatostatin receptor SSTR1; 
however, expression of these clones in COS cells did not result in binding of 
somatostatin peptides but rather opioids, possessing delta- and kappa-like 
pharmacology  respectively. The rat kappa opioid receptor was reported independently 
just weeks later by Minami et al and in the ensuing months, a number of other labs 
reported independent discoveries of kappa receptors as well (Chen, Mestek, Liu, & Yu, 
1993; S. Li et al., 1993; Meng et al., 1993; Minami et al., 1993). 
Overall, the mu, delta, and kappa receptors show about 70% sequence homology 
in the transmembrane regions and 60% in the loop regions; however, whereas the 
intracellular loops show about 90% homology, the N- and C- termini and extracellular 
loops 2 and 3 show virtually none (Figure 2; Kane, Svensson, & Ferguson, 2006). Across 
rodent and human receptors, there is >90% sequence homology (Knapp et al., 1995). All 
three receptors are members of the rhodopsin-like class A GPCR sub-family and are 
negatively coupled to adenylate cyclase via a pertussis toxin sensitive G-protein 
mechanism (Piros, Hales, & Evans, 1996).   
A fourth, previously unknown member of the opioid receptor family was cloned 
independently by a number of labs, sharing 45-55% similarity overall with the mu, delta, 
and kappa receptors ((Bunzow et al., 1994; Mollereau et al., 1994; Y-X Pan, Cheng, Xu, & 
Pasternak, 1994; Wick et al., 1994). Named by Mollereau et al as “Opioid Receptor-Like” 
or ORL, this receptor is actually evolutionarily more ancient, and provides a bridge from 
a common ancestor from which all vertebrate opioid receptors descend. ORL and KOR 
can be grouped together on the basis of their greater similarity, as can MOR and DOR, as 
is evident from a phylogenetic analysis of their sequences (Figure 3, (Stevens, Brasel, & 
Mohan, 2007)). 
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Figure 3: Opioid receptor phylogeny in vertabrates.  
Mu (MOR), Delta (DOR), and Kappa (KOR) opioid receptor sequences from six 
vertebrate species were used to generate a phylogenetic tree, rooted with rhodopsin 
(RHO). Values in each box represent the mean ± SEM diverengence within each 
receptor family, and length of each branch is proportional to the differences of each 
sequence. The arrow denotes the bifurcation between MOR and DOR sequences from 
KOR and ORL sequences. Human, Homo sapiens (h); mouse, Mus musculus (m); rat, 
Rattus norvegicus (r); leopard frog, Rana pipiens (rp); rough-skinned newt, Taricha 
granulosa (tg); and the zebrafish, Danio rerio (dr). Reproduced from (Stevens, 2015). 
Mu Opioid Receptor Multiplicity Redux: Antisense, Splicing, and M6G 
The discovery of single genes for each of mu, delta, and kappa opioid receptors 
seemed at first to be at odds with the vast literature on receptor subtypes as defined 
pharmacologically. However, knowledge of the gene sequences permitted the design of 
antisense oligonucleotides directed toward specific regions of the receptor mRNA, 
resulting in the selective degradation of these mRNAs by the endonuclease RNase H or 
steric blocking of translation ((Dias & Stein, 2002). Thus, the next phase in the story of 
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receptor multiplicity involved the use of these probes, which exhibited dramatically 
more selectivity than the available agonist and antagonist drugs previously used to 
define receptor subtypes.  
The Pasternak laboratory utilized antisense oligonucleotides (ODNs) directed 
against the newly discovered MOR-1 (G. Rossi, Pan, Cheng, & Pasternak, 1994), DOR-1 
(Standifer, Chien, Wahlestedt, Brown, & Pasternak, 1994), and KOR-1 (Chien & 
Pasternak, 1995) genes, confirming that the loss of these single genes alone was 
sufficient to impair analgesia of morphine, DPDPE, or (-)-pentazocine, respectively. 
Critically, however, antisense ODNs targeted to different regions of the receptor mRNA 
did not uniformly block the analgesia produced by mu, delta, or kappa analgesics (K. R. 
Pasternak, Rossi, Zuckerman, & Pasternak, 1999; G C Rossi, Pan, Brown, & Pasternak, 
1995; Grace C Rossi, Su, Leventhal, Su, & Pasternak, 1997), suggesting that while a single 
gene mediated their effects, the complex subtypes observed pharmacologically might 
be explained by the existence of splice variants of these receptor genes. 
Organisms have evolved metabolic pathways to minimize the toxicity of 
xenobiotic compounds, acting to increase the water-solubility of the parent compound 
to facilitate elimination in urine. Whereas phase I biotransformations of xenobiotics 
consist of oxidation, reduction, and hydrolysis reactions to unmask polar functional 
groups on the parent molecule, phase II biotransformations involve conjugating polar 
moieties to the parent molecule – primarily in the form of sulfate, glutathione, and 
glucuronic acid conjugates (Liston, Markowitz, & DeVane, 2001). Most phase II 
biotransformations yield metabolites with dramatically decreased activity at their 
cognate receptors relative to their parent forms, but M6G is an important exception. 
Although the conjugation of the phenolic 3-OH position of the morphinan scaffield by 
the UDP-dependent glucuronide transferase enzyme UGT2B7 yields a compound with 
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negligible affinity for mu receptors, the affinity of M6G for mu receptors is actually 
somewhat higher than morphine itself (Coffman, Rios, King, & Tephly, 1997; G. W. 
Pasternak, Bodnar, Clark, & Inturrisi, 1987). Given subcutaneously, M6G is 
approximately 2-fold more potent than morphine in a tail flick assay. However, given 
i.c.v. or i.t., M6G is 90- and 650-fold more potent than morphine, respectively, which 
cannot be explained on the basis of binding affinity or efficacy at MOR-1 alone (Paul, 
Standifer, Inturrisi, & Pasternak, 1989). The difference between systemic and 
supraspinal/spinal potencies is believed to be pharmacokinetic, as the polar glucuronide 
moiety reduces the ability of the drug to cross the blood brain barrier (Yoshimura, Ida, 
Oguri, & Tsukamoto, 1973).  
The dramatically increased potency of M6G has important clinical ramifications – 
the area under the curve (AUC) in plasma for M6G exceeds morphine by a factor of 9:1 
after morphine oral administration (Osborne, Joel, Trew, & Slevin, 1990), and may be 
substantially higher in patients with impaired renal function (Osborne, Joel, & Slevin, 
1986). In fact, after taking into account the relative potencies of morphine and its 
glucuronide metabolites, concentrations measured in cerebrospinal fluid suggest that a 
majority of the analgesic effect observed after morphine administration is actually due 
to M6G rather than morphine itself (Hand et al., 1987). Recent estimates suggest that as 
much as 96.6% of the analgesic effect of an oral dose and 85.4% of an intravenous dose 
of morphine is likely due to M6G rather than morphine (Klimas & Mikus, 2014). 
Using antisense mapping, Rossi et al demonstrated that antisense ODNs targeted 
to exons 1 and 4 blocked supraspinal morphine analgesia, while ODN’s targeted to 
exons 2 and 3 failed to have any significant effect (G C Rossi, Pan, et al., 1995). In 
contrast, supraspinal M6G analgesia was blocked by antisense ODNs targeted to exons 2 
and 3 but not exons 1 and 4. The strict exon boundaries observed by antisense mapping  
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Figure 4: Antisense mapping MOR-1. 
Antisense probes designed against different exons of the MOR-1 gene shows 
differential exon requirements for morphine and M6G analgesia, supporting a model 
where different splice variants mediate the effects of each drug. Reproduced from (G. 
W. Pasternak & Standifer, 1995), based on data from (G C Rossi, Pan, et al., 1995). 
suggested that alternative splicing could explain the pharmacological differences 
observed between morphine and M6G despite the presence of only one mu opioid 
receptor gene. 
 In rats, antisense ODNs directed against the 5’ untranslated region (UTR) 
encoded by exon 1 of the MOR-1 gene significantly attenuated morphine and DADLE 
analgesia, but were ineffective against M6G, consistent with the results obtained in 
mice and reinforcing the importance of exon 1 in morphine but not M6G analgesia (G C 
Rossi, Standifer, & Pasternak, 1995).  Antisense ODNs directed against G-proteins 
suggested that effector pathways activated by morphine or M6G diverged as well. In 
rats, Giα2 probes blocked morphine analgesia while Giα1 probes had no significant 
effect, while M6G analgesia was blocked by ODNs targeting Giα1 but not Giα2. These 
results were exactly paralleled in mice, where it was found that both supraspinal and 
spinal morphine analgesia was blocked by Giα2 antisense but unaffected by Giα1 
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antisense, while the converse was true for M6G (Standifer, Rossi, & Pasternak, 1996). 
Additionally, both supraspinal and spinal M6G analgesia was reduced by Gx/zα antisense, 
which had no effect on morphine at either site.  
  Still more evidence for independent receptor mechanisms for morphine and 
M6G came from experiments with the spontaneously mu-deficient CXBK mice. As 
previously noted, supraspinally and systemically administered morphine analgesia is  
profoundly impaired in these animals; however, a survey of other “mu” analgesics 
displayed strikingly different sensitivity in the CXBK mouse. M6G i.c.v. analgesia was 
completely intact, as was heroin (s.c.), the heroin metabolite 6-acetylmorphine (i.c.v.), 
and the extremely potent and clinically used fentanyl (G C Rossi, Brown, Leventhal, 
Yang, & Pasternak, 1996); Figure 5). Methadone analgesia was also found to be 
unaffected (Chang, Emmel, Rossi, & Pasternak, 1998).  
 
Figure 5: CXBK sensitivity to opioid analgesics. 
Approximately equipotent doses of various opioids were administered to wildtype CD-1 
or spontaneously mu-deficient CXBK mice. Despite loss of morphine analgesia 
systemically (shown here) and supraspinally (see Figure 1), analgesia produced by a 
number of other drugs classically considered “mu” analgesics was fully intact in these 
animals. Reproduced from Pasternak and Pan, 2013; adapted from data from Rossi et al 
1996 and Chang et al 1998. 
21 
 
Scatchard analysis of 3H-M6G binding in calf striatum reveals the presence of a 
very high affinity but very low abundance site (KD = 68 pM, Bmax = 6.5 fmol/mg of 
protein), in addition to a somewhat lower affinity, but higher abundance site (KD = 1.9 
 
 
Figure 6: 3H-M6G binding and selective antagonism of M6G and heroin analgesia by 3-
methoxynaltrexone.  
(Top) M6G competition of 3H-M6G binding in calf brain homogenate reveals the 
presence of high and low affinity sites; however, in a cell line stably expressing MOR-1, 
only the lower affinity site is observed. Reproduced from (Brown, Yang, Ouerfelli, et al., 
1997). (Bottom) At low doses, 3-methoxynaltrexone selectively antagonizes supraspinal 
M6G and 6-acetylmorphine analgesia and systemic heroin analgesia. Reproduced from 
(Brown, Yang, King, et al., 1997). 
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nM, Bmax = 82 fmol/mg of protein) appearing to correspond to the traditional mu opioid 
receptor on the basis of competition studies(Brown, Yang, Ouerfelli, et al., 1997). The  
high affinity component varied in abundance across brain regions, comprising as much 
as 25% of frontal cortex and striatum binding by homologous competition with 
unlabeled M6G, while appearing absent entirely from the thalamus, which expresses 
very high levels of the traditional mu receptor. Furthermore, the site was not present in 
CHO cells stably expressing the MOR-1 gene. Importantly, 3-methoxynaltrexone, which 
competed 3H morphine with only modest affinity, also showed biphasic competition of 
3H-M6G with a high affinity and low affinity compenent. Further behavioral studies 
showed that 3-methoxynaltrexone antagonized i.c.v. M6G and 6-acetylmorphine and 
systemic heroin analgesia an order of magnitude more potently than morphine (Brown, 
Yang, King, et al., 1997). 
Following the antisense evidence supporting the existence of a separate 
receptor mediating heroin and M6G analgesia which did not depend on exon 1-
associated variants, several groups tested M6G in different MOR exon 1 knockout 
mouse models with conflicting results. Initial attempts by the Uhl group found that both 
heroin and M6G analgesia were lost in the an MOR-1 exon 1 knockout model and 
suggested that there was, in fact, no support for an independent receptor mechanism 
(Kitanaka, Sora, Kinsey, Zeng, & Uhl, 1998). However, a second MOR-1 exon 1 knockout 
animal was generated in the Pintar lab sparing a large portion of the promotor region 
spanning upstream of exon 1 which had been knocked out by the Uhl targeting vector 
(A. G. P. Schuller et al., 1999). In these animals, morphine was completely inactive  
systemically at doses >19-fold higher than its analgesic ED50, while M6G and heroin 
retained full analgesic efficacy with only 2-3-fold shift in ED50 (Figure 7). Furthermore, 
M6G analgesia was still sensitive to mu antagonists as well as exon 1 antisense  
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Figure 7: Morphine, M6G and heroin analgesia in Pintar’s MOR exon 1 knockout 
mouse model.  
In a tail flick assay, morphine analgesia is completely lost at doses >19-fold higher than 
its analgesic ED50. Consistent with antisense studies, M6G and heroin analgesia retains 
full efficacy and dose response curves are only slightly shifted, 2-3-fold. Reproduced 
from (G. W. Pasternak & Pan, 2013) based on data from (A. G. P. Schuller et al., 1999). 
treatment, and 3H-M6G binding was present but at low levels, consistent with retention 
of the low abundance site wildtype brains. Finally, RT-PCR using probes spanning exons 
2 and 3 confirmed the presence of opioid receptor transcripts which lacked exon 1. 
Mu Opioid Receptor Splice Variants 
C-terminal Splice Variants 
Mu opioid receptor gene homologues evolved early in vertebrate evolution, appearing 
first in teleosts as a gene comprised of 5 exons, each encoding a portion of the 7 
transmembrane domains that make up the receptor(Herrero-Turrion & Rodríguez, 
2008). Beginning in zebrafish, the introns separating exons 3-5 disappear to form a gene 
of 3 exons, while a 4th exon is first seen in the chicken. This 4 exon structure is 
conserved across amphibian, reptile, and mammalian species, and share >71% amino 
acid identity. The first exon encodes the extracellular N-terminal region as well as  
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Figure 8: Gene Structure of Mouse, Rat, and Human Mu Opioid Receptor (OPRM-1). 
OPRM-1 undergoes extensive splicing, and exon structure is largely conserved across 
mammalian species. Boxes indicate exons and arrows indicate promoters. Genomic 
distances are indicated but are not to scale. Reproduced from (G. W. Pasternak & Pan, 
2013). 
the first transmembrane domain, with exons 2 and 3 encoding the remaining 6 
transmembrane domains and exon 4 encoding the intracellular C-terminal tail.  
However, predictions that the mu opioid receptor underwent alternative mRNA 
splicing were correct, and in the last 2 decades a dizzying array of additional exons and 
dozens of mu opioid receptor variants have since been discovered (Figure 8 - 10; L. Pan 
et al., 2005; Y. X. Pan et al., 1999; Y. Pan et al., 2005; Ying-Xian Pan et al., 2001; D. A. 
Pasternak et al., 2004; Xu, Xu, Rossi, Pasternak, & Pan, 2011). The first series of variants  
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discovered differ at their 3’ ends, where different exons encode for C-terminal tails. 
These differ dramatically in both length as well as residues predicted to be subjected to 
post-translational modification (Figure 9). These differences are likely to have profound 
implications for receptor pharmacology following agonist binding, as the C-terminal tail 
is believed to recruit intracellular proteins to the receptor signalosome, altering  
 
 
Figure 9: C-terminal Splice Variants of OPRM-1.  
Mouse, rat, and human c-terminal splice variant amino acid sequences are shown with 
symbols indicating predicted phosphorylation sites. Given the importance of 
phosphorylation in recruitment of b-arrestin, these differences are likely to have 
significant consequences on G-protein independent signaling and agonist bias. 
Reproduced from (Ying-Xian Pan, 2005). 
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Figure 10: Mouse OPRM-1 splice variants and protein product.  
Splice variants can be sorted into 3 groups – those that produce a full-length, 7TM 
receptor; variants producing truncated 6TM variants lacking the N-terminus and first TM 
domain but expressing TMs 2-7 and a C-terminal tail; and variants encoding a single TM 
domain. Reproduced from (G. W. Pasternak & Pan, 2013). 
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signaling and trafficking (Georganta, Agalou, & Georgoussi, 2010; Venkatakrishnan et al., 
2013). Indeed, recycling of the receptor back to the cell surface following agonist-
induced internalization is facilitated by the presence of an endocytic recycling sequence  
 that is notably absent from several splice variants such as MOR-1B, D, and E. These 
variants show significantly reduced recycling of these mutants relative to MOR-1 
(Tanowitz, Hislop, & von Zastrow, 2008).  
Finally, phosphorylation of the C-terminal tail has been shown to be involved in 
the recruitment of arrestins, proteins involved not only in the desensitization of 
receptors but also in G-protein independent signaling (Nobles et al., 2011; Reiter, Ahn, 
Shukla, & Lefkowitz, 2012; Xiao, Shenoy, Nobles, & Lefkowitz, 2004). b-arrestin 2 
knockout mice show greater analgesia following morphine treatment than wildtype 
animals (Bohn et al., 1999), yet display reduced development of tolerance, constipation, 
and respiratory depression (Bohn, Gainetdinov, Lin, Lefkowitz, & Caron, 2000; Raehal, 
Walker, & Bohn, 2005).  
As different agonists stabilize slightly different activated conformations of GPCRs 
with differing affinity for arrestins and G-proteins, these agonists will also signal via G-
protein dependent and independent pathways to a greater or lesser degree despite 
binding the same receptor. This phenomenon, termed “Biased Agonism,” has recently 
become an area of intense research (Lohse & Hoffmann, 2014), but to date little is 
known about the effect of alternative splicing, C-terminal tail phosphorylation sites, and 
cell-type specific effects on receptor trafficking and G-protein independent signaling 
mechanisms. 
N-terminal Splice variants 
 In addition to the C-terminal splice variants which feature identical binding 
pockets but differ in their tail region, a second group of MOR splice variants was 
29 
 
identified by Pan et al in 2001 which help explain the remarkable retention of M6G and 
heroin analgesia in Pintar’s MOR exon 1 knockout animals despite total loss of morphine 
analgesia. Associated with exon 11, an exon found a distant 30kb upstream of exon 1 
with its own independent promoter region, a subset of these splice variants skip exon 1  
entirely, producing N-terminally truncated product with only 6 transmembrane domains 
(Figure 10). Despite loss of this first TM domain, these truncated proteins are expressed 
in a region-specific manor throughout the brain and spinal cord, albeit at lower levels 
than the full length MOR-1 (Abbadie, Pan, & Pasternak, 2004; Ying-Xian Pan et al., 2001). 
Despite perceptions that these truncated receptors were unlikely to be 
functionally active as they fail to conform to the canonical 7TM architecture shared by 
the GPCR family, generation of an MOR exon 11 knockout animal confirmed the 
physiological relevance of the 6TMs (Ying-Xian Pan et al., 2009).  These animals retain 
the majority of their full length MOR receptors, with approximately 20% lower 3H-
DAMGO Bmax observed due to loss of 7TMs which include exon 11 as well as exon 1 
(Figure 10). Behaviorally, morphine and methadone retain full efficacy in these animals 
without significant loss of analgesic potency; in stark contrast, drugs such as heroin, 
fentanyl, and M6G showed dramatic shifts in analgesic potency (>5, >9, and 21-fold, 
respectively; Figure 11), consistent with an important role of exon 11-associated splice 
variants in their actions. Taken together with the results antisense mapping and 
reciprocal MOR exon 1 knockout animal from Pintar’s group which expresses only 
truncated 6TM but not 7TM MOR splice variants, the evidence overwhelmingly supports 
a model   M6G and heroin act not only at the traditional mu receptors which mediate 
morphine’s effects, but also a pharmacologically and genetically distinct population of 
receptors involving truncated 6TM receptors. 
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Figure 11: Selective loss of opioid analgesia in MOR exon 11 knockout animals. 
Morphine and methadone analgesia was only slightly shifted in MOR exon 11 knockout 
relative to wildtype controls. However, M6G, heroin, and fentanyl showed dramatic loss 
of analgesic potency, consistent with a critical role of exon 11-associated splice variants 
in mediating their analgesia. Reproduced from (Ying-Xian Pan et al., 2009). 
Recent Insights into Opioid Receptor Structure and Function 
 The crystal structures for all 4 opioid receptors were recently solved by the labs 
of Brian Kobilka and Ray Stevens through the use of cocrystalized antagonists and T4 
lysozyme fusions in the intrinsically disordered 3rd intracellular loop of the receptors, 
providing an evolutionary leap forward in our understanding of molecular recognition 
and selectivity features of the receptors (Granier et al., 2012; Manglik et al., 2012; A. 
Thompson et al., 2012; Wu et al., 2012). Mu receptors were crystallized in a multimeric 
form, consistent with numerous studies supporting receptor homo- and hetero-
dimerization and conformational crosstalk between opioid receptors and other GPCRs 
(Alfaras-Melainis, Gomes, Rozenfeld, Zachariou, & Devi, 2009; Cussac et al., 2012; Cvejic 
& Devi, 1997; Gomes et al., 2013; Jordan & Devi, 1999; Kabli, Fan, O’Dowd, & George, 
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2014; Y-X Pan, Bolan, & Pasternak, 2002; Rozenfeld & Devi, 2007; Rutherford et al., 
2008; Sarkar, Sengupta, Zhang, Boyadjieva, & Murugan, 2012); however, it is too early 
to say whether the interactions observed in the crystal structures represent a 
physiologically relevant  protein-protein interaction interface or are artifacts of the 
unnatural conditions used to grow crystals for x-ray diffraction studies (Roth BL, 
personal communication). Future crystal structures examining opioid receptors in 
complex with agonists, G-proteins, and b-arrestin will further elucidate the mechanics of 
opioid receptor signaling and advance attempts at rational drug design, especially in 
designing biased ligands. 
Interestingly, the 1st transmembrane domain does not make contacts with the 
ligands in the crystal structure of the mu opioid receptor, raising the question of 
whether loss of this TM would substantially perturb ligand binding. This appears to be a 
common structural feature of GPCRs (Venkatakrishnan et al., 2013). Further studies are 
needed to determine whether the 6TM receptors are in fact capable of binding drug or 
activating downstream effectors on their own, or whether they require a partner to 
function once at the cell surface. 
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Chapter 2: Materials and Methods 
Chemicals: Drugs were obtained from the Research Technology branch of the 
National Institute on Drug Abuse (Rockville, MD), Tocris Bioscience (Bristol UK), or 
Caymen Chemical (Ann Arbor, MI). [35S]-GTPγS and Na125I were purchased from Perkin 
Elmer (Waltham, MA). Miscellaneous chemicals and buffers were obtained from Sigma 
Aldrich (St. Louis, MO). IBNtxA and 125I-BNtxA were synthesized and structures 
confirmed as previously described (Majumdar, Burgman, et al., 2011). 
In Vivo Assays 
Animals: C57Bl/6 mice (24–37 g) were purchased from Jackson Laboratories or 
Charles River Laboratories. MOR Exon 11 knockout animals were derived as previously 
described (Pan et al 2009) and backcrossed at least 10 generations on a C57Bl6/J 
background. Double exon 1/exon 11  knockout mice (E1/E11 KO) on a mixed 129-
C57BL/6 background were generated as previously reported (Lu et al., 2015). Exon 1 
MOR-1,  KOR-1, DOR-1, ORL1, and triple KO (TKO) were generated in the laboratory of 
John Pintar (Zhang et al 1998, Schuller et al 1999, Zhu et al 1999, Clarke 2002) and were 
maintained on an inbred 129S6 background.  Animals were given at least 1 week 
washout period after receiving a drug before repeat testing. 
Male Sprague Dawley rats were obtained from Charles River Laboratories. All 
rats were maintained on a 12-h light/dark cycle with Purina rodent chow and water 
available ad libitum and housed in groups of two until testing. All animal studies were 
approved by the Institutional Animal Care and Use Committee of the Memorial Sloan-
Kettering Cancer Center.  
All rats and mice were maintained on a 12-h light/dark cycle with Purina rodent 
chow and water available ad libitum. Mice were housed in groups of five until testing. 
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All animal studies were approved by the Institutional Animal Care and Use Committee of 
Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, or UMDNJ-
RWJMS and performed in accordance with the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals in an Association for Assessment and 
Accreditation of Laboratory Animal Care accredited facility.  
Analgesia Assays: Analgesic dose response curves were generated using a 
radiant heat tail-flick paradigm as previously published with a Ugo Basile 37360 tail flick 
unit (Varese, Italy).  A maximum cutoff latency of 10 seconds was employed to minimize 
tissue damage and data is presented as % Maximum Possible Effect (%MPE) according 
to the formula: %MPE = [(Observed latency - Baseline latency) / (10s - Baseline latency)]. 
Similar results were obtained when data was analyzed quantally with analgesia defined 
as a doubling of baseline latency. The hot plate assay was performed at 55 °C (Ugo 
Basile). The time(s) elapsing to the first pain response (hind paw licking or jumping) was 
scored. A maximal latency of 30 s was used to minimize any tissue damage. ED50 values 
were determined using nonlinear regression analysis where indicated (Graphpad Prism, 
La Jolla, CA) and curves were compared using extra-sum of squares F-test. Where 
indicated, group means for individual doses were compared using 2-way ANOVA and 
post-hoc Bonferroni multiple comparisons test. 
For compounds injected subcutaneously (s.c.), analgesia was tested 30 min post-
injection at peak effect. Compounds delivered intracerebroventricularly (i.c.v.) were 
performed as previously described (Haley and McCormick, 1957). Briefly, the mice were 
anesthetized by isoflurane. A small incision was made, and compounds (2 ul/mouse) 
were injected using a 10 uL Hamilton syringe fitted to a 27 gauge needle. Injections 
were made into the right lateral ventricle at the following coordinates: 2 mm caudal to 
bregma, 2 mm lateral to sagittal suture, and 2 mm in depth. Mice were tested for 
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analgesia 10 minutes following i.c.v. injections. DPDPE, U50, 488, and clonidine were 
also administered intrathecally (i.t.) via lumbar puncture (1ul) as previously described 
(Paul, Standifer, et al JPET 1989; Hylden and Wilcox, 1980). Mice were tested for 
analgesia 15 minutes after i.t. injections.  
Open Field Locomotor Activity: Open field locomotor activity was obtained in a 
MedAssociates ENV-510 activity chamber (St Albans, VT) using MedAssociates Activity 
Monitor software. Animals were habituated to the testing room for at least an hour 
prior to testing each day. Animals were injected s.c. with clonidine and immediately 
placed in the open field box for 60 min, followed by saline the following day; for 
buprenorphine, saline was tested on day 1 and buprenorphine on day 2. Total distance 
traveled as well as distance travelled in 5 min bins were compared using a repeated 
measures ANOVA followed by Bonferroni’s multiple comparisons test. 
Conditioned Place Preference: The testing apparatus consisted of two 
compartments of equal size separated by a wall with a guillotine-style door (ENV-512 
insert; MedAssociates). One compartment was surrounded by white walls and had a rod 
floor, and the other had black walls and a grid floor. Infrared photobeams lining the 
floor tracked the location of the mouse at all times. Animals were habituated to the 
environment for 3 h for each of 2 d before testing and for 1 h on each conditioning 
session. Baseline preferences were determined on the preconditioning test day by 
letting animals explore both sides freely for 20 min, and the side in which they initially 
spent more time in was assigned to saline in the place preference study. Animals were 
injected on alternating days for 8 d with either drug or saline and restricted to one 
compartment for 20 min. On the postconditioning testing day, animals were placed in 
the side paired with saline and allowed to freely explore both compartments for 20 min. 
The time spent in each compartment postconditioning was calculated and subtracted 
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from the amount of time spent in each compartment preconditioning to determine the 
change in each animal’s preference attributable to conditioning. 
Conditioned Place Aversion: Conditioned place aversion was assessed using an 
unbiased 2-chamber conditioned place preference insert in the activity chamber 
(MedAssociates ENV-510) and the animals’ position monitored using Activity Monitor 
software. Animals were habituated to the testing room for at least an hour prior to 
testing each day. On day 1, animals were allowed to freely explore both sides of the 
apparatus. On days 2-4, animals were injected s.c. with saline and immediately placed 
into one side off the apparatus for 20 minutes; in the afternoon, they were injected s.c. 
with 5mg/kg U50,488 which was paired with the opposite side. Animals were randomly 
assigned to receive drug paired with one side and saline in the other such that 50% of 
the animals were conditioned to associate the drug with each side. On day 5, animals 
were again allowed to freely explore both sides of the apparatus.  The amount of time 
spent in each compartment post-conditioning vs. pre-conditioning was compared using 
a 2-way repeated measures ANOVA followed by a post-hoc Bonferroni’s multiple 
comparisons test (Graphpad Prism). The total distance traveled by each animal after 
receiving drug on each of the 3 conditioning days was also recorded and normalized to 
the distance travelled after receiving saline that morning. 
Gastrointestinal Motility Assay: Gastrointestinal transit was measured as 
previously described (Pan et al., 2009). Briefly, animals were injected with either saline 
or buprenorphine and 10 minutes later received a charcoal meal (10% charcoal and 
2.5% gum tragacanth in distilled water) by gavage. 30 minutes after administration of 
the charcoal meal, animals were sacrificed by cervical dislocation and the distance 
travelled by the charcoal meal was measured and expressed as a fraction of the total 
distance from the pyloric sphincter to the cecum.  
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Respiratory Depression Assays: Respiratory rate was assessed in awake, freely 
moving, adult male CD1 mice with the MouseOx pulse oximeter system (Starr Life 
Sciences). Each animal was habituated to the device for 30 min and then tested. A 5-
second average breath rate was assessed at 5-min intervals. A baseline for each animal 
was obtained over a 25-min period before drug injection, and testing began at 15 min 
post-injection and continued for a period of 35 min. Groups of mice (n = 5) were treated 
s.c. with either morphine (20 mg/kg) or IBNtxA (2.5 mg/kg) at doses approximately four 
times their analgesic ED50. Groups were compared with repeated-measures ANOVA 
followed by Bonferroni multiple-comparison test. 
Tolerance and Dependence Studies (Mice) Tolerance was induced by twice-daily 
injections with either morphine (6 mg/kg s.c.) or IBNtxA (1 mg/kg s.c.) or through the 
implantation of free-base morphine pellets (75 mg). Dependence was determined on 
day 3 after pellet implantation with either IBNtxA (1 mg/kg s.c.) or naloxone (1 mg/kg 
s.c.) to precipitate withdrawal, and animals were evaluated for signs of diarrhea and 
jumping. 
Cross-Tolerance Assays (Rats) To assess for cross tolerance between IBNtxA and 
morphine, rats (n=4) were made tolerant to morphine by the subcutaneous 
implantation of three 75mg pellets of morphine freebase under isoflurane anaesthesia 
(Yoburn, et al., 1985). A control group (n = 10) was implanted with placebo pellets. 
Three days after pellet implantation, animals were administered escalating doses of 
IBNtxA and tested in the tail-flick analgesia assay as above. The following day, animals 
were administered escalating doses of morphine and tested in the tail-flick analgesia 
assay as above to confirm that the morphine-pelleted animals were indeed morphine 
tolerant. At the conclusion of the morphine dose-response assay, all animals were given 
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naloxone 1mg/kg and observed for wet dog shakes for 15 minutes to confirm that the 
morphine-pelleted animals were indeed physically dependent on morphine. 
Lentiviral Injection: Detailed methods have been previously described (Lu et al., 
2015). Lentivirus was generated using constructs with and without the mMOR1G 
sequence in HEK293T cells. Four µl of the lentiviral particles expressing mMOR1G or 
vector alone were injected supraspinally on days 1, 3, and 5. All drug testing was carried 
out between 5 and 14 weeks post viral injection, during which protein expression 
remains stable. 
In Vitro Assays 
Binding Studies:  125I-IBNtxA binding assays were carried out in rat brain 
membrane homogenates prepared as previously described (Majumdar, Grinnell, et al., 
2011)  at a concentration of 0.5 - 1 mg protein/mL.  To prevent binding to traditional 
opioid receptors, binding was carried out in the presence of mu (CTAP), kappa1 
(U50,488H), and delta (DPDPE) blockers at a final concentration of 250 nM each.  
125I-IBNtxA and 125I-labeled photoaffinity ligand binding assays were carried out 
in CHO cells stably expressing mMOR-1, mDOR-1, or mKOR-1 receptors, prepared as 
described previously (Majumdar, Burgman, et al., 2011), with 3-10 µg protein in a 
volume of 0.5-1 mL of homogenate.  
Nonspecific binding was determined in the presence of levallorphan (1 µM) and 
specific binding is reported.  Binding was carried out for 90 min (equilibrium) at 25oC 
using 0.5 to 1 ml of homogenate.  Glass fiber filters were soaked in 0.5% 
polyethyleneimine for at least 15 minutes prior to filtration to minimize nonspecific 
binding to the filters.  
Stimulation of 35S-GTPγS binding:  [35S]-GTPγS Assays were performed based upon  
published methods (Selley et al., 1998; Bolan et al., 2004; Pan et al., 2005).   Membrane 
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homogenates from C57 mouse brain (25 µg protein) or CHO cells stably transfected with mMOR, 
mDOR, or mKOR (50 µg protein) were incubated for 1 hr at 30oC with the indicated drug, 35S-
GTPγS (0.05 nM) and GDP in a final volume of 1mL assay buffer containing Tris HCl (50 mM; pH 
7.4 at 37oC), MgCl2 (3 mM), EGTA (0.2 mM), NaCl (100 mM), and a protease inhibitor cocktail 
(leupeptin, bestatin, aprotinin, and peptstatin). GDP concentrations were optimized for each 
receptor assay:  DOR-1 and KOR-1, 10µM; MOR-1, 30µM; brain, 60µM).  Nonspecific binding was 
assessed by the addition of 100µM cold GTPγS. Binding was terminated by vacuum filtration 
through Whatman GF/C glass fiber filters which were rinsed 3x2mL with cold Tris HCl. Filters 
were cut out and 3mL of scintillation fluor (Liquiscint, National Diagonistics, Atlanta, GA) was 
added to each tube and incubated at room temperature for at least 2 hours before being 
counted on a Packard Tri-Carb TR-2900 liquid scintillation counter. 
β-Arrestin-2 Recruitment Assay:  β-arrestin-2 recruitment was determined using 
the PathHunter enzyme complementation assay (DiscoveRx. Fremont, CA) using 
modified MOR-1 in CHO cells (a gift from DiscoveRx).  Cells were plated at a density of 
2500 cells/well in a 384-well plate as described in the manufacturer’s protocol. The 
following day, cells were treated with the indicated compound for 90 minutes at 37°C 
followed by incubation with PathHunter detection reagents for 60 minutes. 
Chemiluminescence was measured with an Infinite M1000 Pro plate reader (Tecan, 
Männedorf, Switzerland). 
Photoaffinity Labeling 
The indicated 125I-labeled photoaffinity ligand was incubated with 0.5mg-2mg 
protein at a final concentration of 0.3-0.5 nM in a volume of 2mL 50 mM KPO4 (Mu 
receptors) or 50 mM KPO4/5mM MgSO4 in microcentrifuge tubes for 90 minutes at 25C 
to reach equilibrium. Tubes were then centrifuged for 10 min at room temperature at 
20,000g to separate free ligand and rapidly resuspended in 2mL ice-cold KPO and 
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transferred to an acrylic cuvette (Nümbrecht, Germany). Photolysis was initiated in a 
Rayonet photoreactor (RPR-200, Southern New England Ultraviolet Company, Branford 
CT) equipped with 13 RPR-3500 bulbs for irradiation at 350nm for 5 minutes. The 
photolysate was then transferred back to a microcentrifuge tube, centrifuged at 4C for 
10 min, and the supernatant discarded. The pellet was then solubilized at 4C with either 
denaturing (RIPA buffer) or nondenaturing (0.2-0.25wt% MNG-3 in 1X Tris buffered 
saline; Chae et al., 2010) buffer with EDTA-free HALT protease inhibitor cocktail 
(containing AEBSF HCl, Aprotinin, Bestatin, E-64, Leupeptin, Pepstatin A; ThermoFisher 
Scientific, Waltham, MA). The solubilizate was then clarified by centrifugation for 10 min 
at 4C at 20,000g.  
The clarified solubilizate was either directly run on a 10% SDS-PAGE gel (BioRad, 
Berkeley CA) at 300V for 19 minutes following incubation at room temperature for 30 
min with Laemmli sample buffer and 5% b-mercaptoethanol or subjected to further 
purification. BioRad Precision Plus molecular weight markers were used, with 
MagicMark XP western blot molecular weight markers. Gels were transferred to PVDF in 
a BioRad Transblot semi-dry transfer device for 7 min at 2.5A and apposed to film with a 
Kodak Biomax Intensifying Screen at -80C for exposure from 3 hours – 8 days. 
Wheat germ agglutinin (WGA) affinity purification was performed according to 
the manufacturer’s protocol (Vector Labs, Burlingame, CA). Briefly, 25uL of a slurry of 
WGA-agarose beads was transferred to a microcentrifuge tube containing 20 volumes of 
nondenaturing buffer and washed 3 times with 20 volumes of fresh buffer solution. The 
clarified solubilizate was added and rotated for 30 min at room temperature before 3 
washes with 30 volumes of fresh nondenaturing buffer. The target was then eluted 
twice using N-acetylglucosamine elution solution (Vector Labs), run through a 7kDa 
MWCO Zeba spin desalting column equilibrated with nondenaturing buffer, and 
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concentrated on a 10kDa NMWL Amicon Ultra 0.5 spin concentrator cartridge to the 
desired final volume. The final product was incubated at room temperature for 30 min 
with Laemmli sample buffer and 5% b-mercaptoethanol and separated by SDS-PAGE as 
above. 
Immunoaffinity purification was also performed under both denaturing and 
nondenaturing conditions, according to manufacturer’s protocols. Solubilizate was 
incubated with rabbit polyclonal antibody directed against the C-terminal tail of the mu 
opioid receptor (C-20, Santa Cruz Biotechnology, Dallas, TX) according to the 
manufacturer’s suggested dilution relative to the protein added, rotating at 4C for 1hr – 
overnight. Antibody-Receptor complexes were then pulled down with Protein A-agarose 
(EzView Red, Sigma Aldrich) for 1-2 hours and equilibrated according to manufacturer’s 
protocols. Beads were washed 2-3 times with 30 volumes buffer until no radioactivity 
could be detected in the wash with a survey meter. For denaturing conditions, beads 
were eluted for 30 min with 6.5M urea, 150mM DTT, and 1X Laemmli sample buffer at 
room temperature and separated by SDS-PAGE as above. For native conditions, beads 
were eluted 2 times with 100 ug/mL MOR C-20 blocking peptide (Santa Cruz 
Biotechnology) for 30 min at room temperature. The eluate was then concentrated in a 
100kDa NMWL Millipore Biomax spin concentrator. 
Blue Native PAGE. Blue native gel electrophoresis was performed according to 
manufacturer’s protocols (Life Technologies, Carlsbad, CA), based on the method of 
(Schägger & von Jagow, 1991). Briefly, samples were prepared by adding glycerol (10% 
final concentration) and Coomassie Brilliant Blue G-250 (0.05-0.0625% final 
concentration). Samples were then loaded onto a 4-16% native gel (Life Technologies) 
and separated for 105-115 minutes at 150V. Gels for imaging were destained in 40% 
MeOH/10% Acetic Acid solution for 15 min, followed by 8% Acetic acid for 1hour, then 
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imaged on a Chemidoc MP (BioRad). Gels for autoradiography were transferred to PVDF 
and apposed to film as above. 
2D Blue Native/SDS-PAGE was performed by excising a lane from a BN-PAGE gel 
and incubating at room temperature in 1% SDS / 1% β-mercaptoethanol with rocking for 
30 min. The highest molecular weight portion of the lane was trimmed to make a 6cm 
strip for insertion into a Life Technologies NuPage Novex 12% Bis-Tris gel with a 2D well. 
Gels were run with MOPS-SDS buffer for 1 hour at 200V per manufacturer’s protocol, 
then transferred to PVDF and apposed to film with an intensifying screen as above. 
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Chapter 3: Characterization of a novel opioid pain reliever, 
IBNtxA, with a superior side effect profile 
Introduction 
Tritium is commonly used as a radioisotope for radiolabeling of drugs in binding 
assays because it is chemically identical to hydrogen and can thus be incorporated into 
any known drug without altering the binding properties of the parent compound. Since 
binding assays depend on counting the number of bound radioligand molecules, as 
specific activity increases, less tissue is required to produce the same number of counts 
observed for a given receptor site; although carbon 14 can be incorporated into 
molecules without altering their binding properties as well, the very low specific activity 
of this isotope prohibits its use for researching sites of low abundance - such as those 
for neurotransmitters in the brain.  
Indeed, poor specific activity of the tritiated and 14C-labeled levorphanol used by Avram 
Goldstein had thwarted his attempts at identifying the opioid receptors (Goldstein et al., 
1971). Likewise, the challenges of discovering opioid receptor subtypes of necessarily 
lower abundance require higher specific activity radioligands. Of course, as specific 
activity is proportional to halflife, short lived isotopes must be prepared more 
frequently. For these reason, the higher specific activity iodine-125 falls into a sweet 
spot - specific activity of a radioiodinated drug is at least 40-fold greater than a typical 
tritiated compound, yet once prepared it can be used without substantial decay for over 
a month. Additionally, after electron capture and transmutation to an excited state 
tellurium-125, the nuclide releases a gamma ray, permitting the use of a gamma 
counter rather the environmentally hazardous scintillation fluor required for high 
efficiency counting of beta particles.  
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Table 1: Commonly used isotopes in biological research 
Isotope Halflife Specific Activity Decay Emission 
3H 12.43 years  28.7 Ci/mmol Beta particle 
14C 5730 year 0.0625 Ci/mmol Beta particle 
125I 59.6 days  2190 Ci/mmol Gamma ray, X-ray, electrons 
35S 87.4 days  1493 CI/mmol  Beta particle 
32P 14.3 days 9128 Ci/mmol Beta particle 
 
For these reasons, Dr. Majumdar set out to make a 125I-labeled radioligands 
based on the mu opioid agonist oxymorphone, as well as the nonselective opioid 
receptor antagonists naloxone and naltrexone (Figure 12) – named IBOxyA, IBNalA, and 
IBNtxA, respectively (Majumdar, Burgman, et al., 2011). 
In the early 1970s, the Snyder lab chose the opioid antagonist levallorphan to 
define nonspecific binding for two important reasons: first, although he was not 
successful at discovering an opiate receptor, Goldstein reasoned that specific binding 
must be stereoselective since only one enantiomer was active behaviorally – both 
enantiomers of levallorphan were available, so it was possible to establish this 
condition. Second, unlike either Terenius or Simon, the Snyder lab initially used 
radioligand 3H-naloxone, an antagonist, which therefore bound both active and inactive 
conformations of the receptor with high affinity; the ideal drug for defining nonspecific 
binding should also have high affinity for both active and inactive conformations, 
precluding the use of an agonists such as methadone or levorphanol which possess high 
affinity only for the active conformation which mediates their effects, but much lower 
affinity for the inactive conformation (G. W. Pasternak & Snyder, 1975). 
The choice of levallorphan decades earlier was fortuitous. Initial binding studies 
performed on 125IBNtxA used levallorphan to define nonspecific binding, and curiously 
the parent opioid receptor antagonists naloxone and naltrexone failed to fully inhibit 
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Figure 12: Iodobenzoyl derivatives of Naltrexone, Naloxone, and Oxymorphone. 
Reproduced from (Majumdar, Burgman, et al., 2011). 
binding in mouse brain. This finding hinted at the existence of another, as yet 
uncharacterized opioid receptor site insensitive to naloxone and naltrexone but 
sensitive to levallorphan. Using a combination of selective mu, delta, and kappa blockers 
confirmed that this binding did not correspond to any of the canonical opioid receptors, 
and binding remained in a triple knockout animal lacking all full length mu, delta, and 
kappa opioid receptors, confirming that it could not correspond to any of these sites – 
yet, the high affinity for levallorphan suggested that it was indeed opiate in nature.  
Years earlier, a compound called 3H-naloxone benzoylhydrazone (NalBzOH) had 
been synthesized to study pseudoirreversible mu opioid binding, but in fact 
demonstrated an additional reversible binding component which was not competed by 
mu- or delta-selective drugs, and thus deemed kappa-like (Price, Gistrak, Itzhak, Hahn, & 
Pasternak, 1989). However, the selective kappa ligand U50,488 failed to compete this 
binding with high affinity, leading to the suggestion that the drug was binding a 
previously unknown kappa subtype, named kappa3. Indeed, NalBzOH competed the 
remaining IBNtxA binding with subnanomolar affinity, suggesting a common target. 
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Surprisingly, binding was found to be lost in a newly generated MOR exon 11 knockout 
mouse selectively lacking truncated splice variants of the mu opioid receptor, but 
retaining full length mu receptors, confirming that the binding was definitely related to 
the mu opioid receptor but did not correspond to the canonical mu sites. After 
obtaining such compelling binding data ex vivo, we sought to characterize the drug in 
vivo to determine the behavioral pharmacology of the drug and its novel target. 
Results 
 IBOxyA and IBNtxA were tested in a radiant heat tail-flick paradigm in mice, under the 
initial assumption that the compound possessing an N-methyl group based on the 
agonist, oxymorphone, would be an analgesic, while IBNtxA, with its N-
cyclopropylmethyl group known to convey antagonist activity at traditional mu sites, 
was expected to behave as an antagonist. To our surprise, OxyIBA failed to increase 
baseline tail flick latencies at any dose tested (not shown), while IBNtxA was a potent 
analgesic with an ED50 of about 0.3 mg/kg (Figure 13A), around 10-fold more potent 
than morphine in this assay. It was also active in a hot plate model of thermal pain with 
similar potency (Figure 13B). Also, the drug was active when given orally, although it  
was around 10-fold less potent via this route (Figure 13C).  
Importantly, when we tested IBNtxA in triple knockout animals, there was no 
significant shift in analgesia, confirming that the analgesia produced was mediated not 
by the drug’s actions at any of the canonical mu, delta, and kappa receptor (Figure 14A). 
This corresponded perfectly with the binding data showing that mu-, delta-, and kappa- 
blocker resistant binding was retained in these animals, and suggested that this binding 
site was indeed responsible for the observed analgesia. Indeed, levallorphan was shown 
to readily reverse IBNtxA analgesia (Figure 14B; ID50 = 0.54 mg/kg s.c.), consistent with 
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Figure 13: IBNtxA analgesia in wildtype CD-1 mice.  
(A) Tail flick analgesia. CD-1 mice were injected s.c. with escalating doses of IBNtxA  
and were tested 30 minutes later at peak effect in a radiant heat tail flick assay. (B) 
Hotplate analgesia. Two groups of CD-1 mice (n = 8) were injected s.c. with escalating 
doses of IBNtxA and were tested independently in a 55 °C hot plate assay. ED50 in this 
assay was = 0.6 mg/kg. (C) Analgesia time course.  Groups of mice received IBNtxA 
administered s.c. (0.75 mg/kg, n = 20) or orally (5 mg/kg by gavage, n = 8) and were 
tested in a tail flick assay at the indicated times. 
its high affinity competition of the non-traditional site in binding assays, while analgesia 
was much less sensitive reversal by naloxone (ID50 = 10.5 mg/kg) than morphine (ID50 = 
0.01 mg/kg). Finally, as predicted by the binding data, the drug’s analgesia was also 
substantially lost in the MOR exon 11 knockout generated by Dr. Pan (Figure 14C), 
confirming the critical role of truncated exon 11-associated splice variants in mediating 
the drug’s actions. The reciprocal knockout findings demonstrate that the site mediating 
IBNtxA analgesia requires truncated exon 11-associated variants but not full length exon 
1-associated variants which are lost in the triple knockout animal.  
We next sought to investigate the side effect profile of the drug. Opiate 
overdose can be lethal, especially in illicit settings as recreational users are not 
monitored for hypoxia or apnea as in a healthcare context. Death occurs primarily due 
to depression of respiration by MORs expressed in the brainstem, where mu agonists 
disrupt both the respiratory rhythm as well as the drive to breathe (Pattinson, 2008). 
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Figure 14: IBntxA analgesia in MOR knockout models and reversal by levallorphan  
(A) IBNtxA analgesia in wildtype and triple opioid receptor knockout animals. Groups of 
mice (n = 10 each) were injected s.c. with escalating doses of IBNtxA and were tested 30 
minutes later at peak effect in a radiant heat tail flick assay. Animals were considered 
“analgesic” when the latency to tailflick was at least 2x their baseline. ED50 values [95% 
Confidence interavals] were 0.22 mg/kg [0.13 – 0.32] for the wildtype C57 group and 
0.39 mg/kg [0.15 – 0.58] for triple knockout mice. (B) Levallorphan antagonism of 
IBNtxA analgesia. Groups of mice (n ≥ 10) were injected s.c. with IBNtxA (0.75 mg/kg) 
along with the indicated dose of levallorphan and were tested in a tail flick assay 30 
minutes later. Levallorphan potently blocked IBNtxA analgesia with an ID50 value ± SEM 
of 0.54 ± 0.05 mg/kg. (C) IBNtxA analgesia in MOR Exon 11 knockout animals. IBNtxA 
analgesia (0.5 mg/kg)  was  determined in the tail flick assay as above in groups (n = 10 
each) of wildtype C57, Triple Knockout, and MOR Exon 11 knockout animals. Although 
there was no difference between wildtype C57 and triple knockout response, Exon 11 
animals expressed significantly lower analgesia relative to both wildtype and Triple KO 
groups (Fisher exact test). 
Animals were injected subcutaneously with saline vehicle, morphine, or IBNtxA 
at equipotent doses approximately 4-5 times their analgesic ED50 and their respiration 
monitored as the animals moved freely about their cages. As expected, morphine 
produced a clinically meaningful and profound depression of respiratory rate of 
approximately 50% lower than their baseline values; IBNtxA did not differ from saline at 
any time point measured. 
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Figure 15: Effects of IBNtxA on respiration.  
Animals were randomly assigned to receive saline (n = 5), IBNtxA (2.5 mg/kg, n = 5), or 
morphine (20 mg/kg, n =5), injected s.c. Each animal’s baseline average breath rate was 
measured every 5 min for 25 min before drug injection, and breath rates after drug 
injection are expressed as a percent of baseline. IBNtxA did not depress respiratory rate 
and was not significantly different from saline at any time point, whereas morphine 
decreased respiratory depression in comparison with both saline and IBNtxA (P < 0.001) 
as determined by repeated-measures ANOVA followed by Bonferroni multiple-
comparison test. 
One often dose-limiting side effect produced by clinically used opiates is constipation. 
This effect is mediated primarily by mu and/or kappa receptors expressed in the gut 
(Culpepper-Morgan, Holt, LaRoche, & Kreek, 1995). Therefore, we investigated whether 
IBNtxA reduced the gastrointestinal motility of a charcoal meal in mice (Figure 16). 
Again, we observed the expected dramatic decrease in GI transit produced by morphine 
at its analgesic ED50. Although some decrease in distance travelled was observed for 
IBNtxA, the magnitude was far less than that seen with morphine, and exhibited a 
ceiling effect across doses several times its analgesic ED50 suggesting a much more 
limited ability to depress GI transit (Figure 16A). More importantly, although analgesia 
was lost in MOR exon 11 knockout mice, the animals still exhibited decreased 
gastrointestinal motility, suggesting that the effect is off-target and can be dissociated  
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Figure 16: Effect of IBNtxA on gastrointestinal transit.  
(A) Groups of mice (n = 10 each) were randomly assigned to receive saline, morphine (5 
mg/kg), or IBNtxA (0.3, 0.6, and 1.5 mg/kg) injected s.c. before receiving an oral dose of 
0.2 mL of charcoal meal (2.5% gum tragacanth and 10% charcoal in water) by gavage. 
Animals were sacrificed 30 min later, and the distance traveled by charcoal was 
measured. IBNtxA lowered transit significantly compared with saline (P < 0.05) but less 
than morphine (P < 0.05) as determined by ANOVA followed by Tukey’s multiple-
comparison test. There was no significant difference between doses of IBNtxA, 
suggesting a ceiling effect on GI transit to doses up to 3 times the analgesic ED50. (B) 
Groups of wildtype C57 or MOR Exon 11 knockout mice (n = 10 for each group) were 
injected with either saline or IBNtxA (1.5 mg/kg) and tested in the GI transit assay as 
above. IBNtxA reduced GI transit relative to saline in both genotypes (p < 0.001,Tukey’s 
multiple comparison test after 1-way ANOVA). 
from the drug’s analgesia (Figure 16B).  
Next, we examined tolerance and dependence to IBNtxA’s analgesic effects 
(Figure 17). As with morphine, chronic dosing of animals with IBNtxA resulted in 
decreasing effectiveness over time; however, this developed much more slowly. Mice 
made tolerant to morphine exhibited profound withdrawal signs such as jumping 
behavior when challenged with a low dose of naloxone, yet animals made tolerant to  
IBNtxA failed to show jumping behavior significantly different from saline controls when 
given either low or high doses of either naloxone or levallorphan. Furthermore, animals 
made highly tolerant to morphine via the implantion of high-dose, slow-release pellets 
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Figure 17: Tolerance and physical dependence to IBNtxA. 
(A) Tolerance. Groups of animals (n ≥ 20) were injected s.c. two times daily with 
equipotent doses of morphine (6 mg/kg) or IBNtxA (1 mg/kg). Analgesia was tested on 
the indicated days to assess the level of tolerance to each drugs’ effects. (B) Physical 
dependence. Groups of animals (n ≥ 10) were injected twice daily for 10 days with either 
morphine (10 mg/kg) or IBNtxA (1 mg/kg). Animals were then injected with a challenge 
dose of saline, naloxone (1 mg/kg, s.c.) or levallorphan (1 mg/kg s.c.) and monitored for 
jumping behavior, a robust sign of withdrawal, for 15 minutes.  Saline produced no 
jumping in any group, while animals chronically treated with morphine exhibited a 
profound withdrawal syndrome (p < 0.001, Tukey’s post-hoc multiple comparisons test 
after one way ANOVA). Neither naloxone nor levallorphan produced significant 
withdrawal signs in animals chronically treated with IBNtxA. 
showed no cross-tolerance to IBNtxA, lending further support to the case that IBNtxA’s 
target is independent of the traditional mu receptor. 
Perhaps the most well-known side effect of mu agonists is euphoria, leading to 
their recreational use, abuse, and addiction.  In a conditioned place preference assay, 
we sought to determine whether IBNtxA produced rewarding behavior (Figure 18). 
When animals were trained to associate morphine with one chamber of the apparatus, 
they developed a strong preference for this side, consistent with its well-established   
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Figure 18: Conditioned place preference experiments with IBNtxA. 
Mice were randomly assigned to receive saline (n = 10), IBNtxA (1 mg/kg, n = 10), or 
morphine (10 mg/kg, n = 13) in a two-compartment conditioned place preference 
assay. IBNtxA did not produce place preference or aversion on the final test day 
relative to pre-conditioning chamber preference, and did not differ significantly from 
saline (P > 0.05), whereas morphine showed preference in comparison with both saline 
and IBNtxA (P < 0.05) as determined by Tukey’s multiple-comparison test following a 
one-way ANOVA. 
rewarding effects; however, animals who were trained with an equipotent dose (2 times 
the analgesic ED50) of IBNtxA failed to exhibit either preference for, or aversion to, the 
drug-paired side relative to saline-treated control animals, suggesting the drug’s abuse 
liability is likely to be substantially improved over morphine. 
Although rats and mice both belong to the family Rodentia and are both 
commonly used animal models in laboratory research, their behavioral responses to 
opiates can differ markedly, meaning that behavioral observations obtained in one 
species may not necessarily be predictive of human response. For instance, although 
administration of morphine to humans results in sedation, mice exhibit increased 
locomotor activity, unlike rats, whose locomotor behavior is depressed. Additionally, 
although mice, rats, and humans all possess homologous truncated exon 11-associated 
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Figure 19: IBNtxA analgesia and sensitivity to naloxone in the rat.  
(A) Groups of rats(n = 4) were assessed for IBNtxA analgesia at peak effect in three 
independent experiments (n = 12 total) in a radiant heat tail flick assay. Animals 
received escalating doses of IBNtxA to generate the analgesic dose response curve. The 
ED50 was 0.89 mg/kg (95% confidence interval, 0.69–1.2). (B) Groups of rats (n = 8) 
received IBNtxA (2 mg/kg) and were tested for analgesia after 30 minutes, immediately 
given levallorphan (1 mg/kg s.c.),and tested 20 minutes later. (C) Groups of rats (n = 4) 
received either morphine (8 mg/kg s.c.) or IBNtxA (2 mg/kg s.c.) immediately after the 
injection of saline or the indicated dose of naloxone. Naloxone significantly blocked 
morphine analgesia (Bonferroni multiple comparison test, P < 0.0001) as well as IBNtxA 
(P < 0.005 at 1 mg/kg, P < 0.01 at 5 mg/kg). (D) To assess the ability of a low dose of 
naloxone to reverse analgesia groups of rats were injected with equivalent analgesic 
doses of morphine 8 mg/kg s.c. (n = 4) or IBNtxA 2 mg/kg s.c. (n = 5). Animals were 
tested in the tail-flick assay after 20 minutes for morphine and 30 minutes for IBNtxA. 
They were then immediately administered naloxone (0.1 mg/kg s.c.) and tested again 
in the tail-flick assay 20 minutes later. Results are reported as percentage of maximum 
possible effect (%MPE). The results for morphine revealed a significant reduction by 
naloxone (paired t test, P , 0.005). There was no significant (ns) naloxone effect against 
IBNtxA. 
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variants of the OPRM-1 gene which encodes the mu opioid receptor, the splicing 
patterns of the rat more closely mimic that of humans (Xu et al., 2011). We therefore 
examined the pharmacology of IBNtxA in the rat.  
As in mice, IBNtxA was a potent analgesic in a radiant heat tail-flick assay, with 
an ED50 for subcutaneous injection of 0.89 mg/kg (Figure 8). This was approximately 2-
fold less potent than was observed in mice, but still about 4-fold more potent than 
morphine in this assay. As in the mouse, levallorphan readily reversed the analgesia 
produced by IBNtxA; however, we were surprised to see that the site was much more 
readily reversed by naloxone, suggesting that the pharmacology of the site does differ 
somewhat from that observed in the mouse.  
Although no opioid receptor knockout rats are currently available, cross-
tolerance experiments were performed to confirm that IBNtxA analgesia was not being 
mediated by the traditional mu site in these animals (Figure 20). Subcutaneous 
implantation of 3 75mg slow-release morphine pellets produced significant tolerance in 
rats, confirmed by a >6-fold shift in the analgesic ED50 of subcutaneously injected 
morphine and significant naloxone precipitated withdrawal the day after cross-tolerance 
testing. Subcutaneous IBNtxA was actually slightly more potent in morphine pelleted 
animals (ED50 = 0.26 mg/kg) relative to animals implanted with placebo pellets (ED50 = 
0.52 mg/kg; p < 0.05).  
IBNtxA’s effects on respiration were also assessed to determine whether 
IBNtxA’s unique side effect profile was similar in the rat as in the mouse (Figure 21). 
Using pulse oximetry, oxygen saturation values were obtained following injection with 
saline, IBNtxA, or morphine at equipotent doses about 4-5 times their analgesic ED50s. 
As expected, morphine produced a substantial decrease in blood oxygen 
saturation, beginning by 15 minutes post-injection and continuing until approximately 2  
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Figure 20: Assessment of cross-tolerance between morphine and IBNtxA in the rat.  
Analgesic cross-tolerance was assessed in groups of rats, each implanted with either 
three morphine (n = 4) or placebo (n = 10) pellets and tested with IBNtxA 72 hours later.  
(A) The following day, cumulative morphine dose-response curves revealed a morphine 
ED50 [95% CI] of 20.5 mg/kg [7.7–54] in the morphine-pelleted rats compared with 3.3 
mg/kg [2.7–4.0] in placebo-pelleted animals (p < 0.001), confirming the development of 
tolerance. (B) After the morphine cumulative dose-response testing, animals received a 
challenge dose of naloxone (1 mg/kg, s.c.) to assess physical dependence. Morphine-
pelleted animals displayed a significantly greater number of wet-dog shakes, a robust 
withdrawal sign in rats, relative to placebo-pelleted controls (p < 0.005). (C) In 
morphine-pelleted animals, the ED50  [95% CI] for IBNtxA was 0.26 mg/kg [0.15–0.45] 
compared with 0.52 mg/kg [0.37–0.75] in the placebo-pelleted rats. 
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Figure 21: Respiratory depression in the rat.  
Rats were randomly assigned to receive saline (n = 4), IBNtxA (4 mg/kg, n = 4), or 
morphine (20 mg/kg, n = 4). Using oximetry, each animal’s O2 saturation was 
measured for 5 seconds every 5 minutes for 25 minutes before and 60 minutes after 
injection of the treatment. There were no differences between IBNtxA and saline at 
any time point, whereas morphine significantly depressed O2 saturation (* = P < 
0.0001 at each time point) from 15–60 minutes as determined by Bonferroni multiple-
comparison test after a two-way repeated-measures ANOVA. 
hours after injection (not shown). In contrast, IBNtxA was indistinguishable from saline 
vehicle treated animals at any time point observed. 
Using the 125I-labeled form of IBNtxA, we investigated the pharmacology of the 
receptor binding site in rat brain membranes as well (Figure 22). As no opioid receptor 
knockout rat models are available, binding was performed in the presence of high 
concentrations (250nM each) of the selective drugs CTAP, DPDPE, and U50,488 to block 
binding of 125IBNtxA to traditional mu, delta, and kappa receptors, respectively. Under 
these conditions, 125IBNtxA bound a low abundance site with very high affinity (Bmax = 15 
+/- 2 fmol/mg protein; KD = 0.22 +/- 0.02 nM). While the affinity for this site was virtually 
identical to the high affinity site observed in the triple knockout mouse brain (KD = 0.16 
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Figure 22: 125IBNtxA binding in rat brain membranes. 
(A) Saturation studies were performed using brain homogenates in the presence of m 
(CTAP), d (DPDPE), or k1 (U50,488H) blockers at 250 nM. Nonspecific binding was 
defined by levallorphan (1 mM). Only specific binding is reported. The assay was 
replicated 3 times, and the results shown are from a representative experiment. 
Nonlinear regression analysis using GraphPad Prism generated an average KD from the 
three independent experiments of 0.22 ± 0.02 nM and a Bmax of 15 ± 2 fmol/mg 
protein. (B) Rat brains were rapidly removed and dissected into the indicated regions, 
and individual homogenates were prepared. Binding in each region was determined 
using [125I]-IBNtxA (0.1 nM) in the presence of mu, delta, and kappa1 blockers (250 nM 
each) and normalized to binding in whole brain processed in parallel. Results are the 
mean ± SEM of three independent experiments. Binding differed across regions (one-
way ANOVA, P = 0.0003), with the thalamus showing significantly more binding than the 
whole-brain control (Bonferroni multiple comparison test, P , 0.01) and the cerebellum 
showing significantly less binding than the whole-brain control (P , 0.05). PAG, 
periaqueductal gray. 
+/- 0.02 nM; Majumdar, Grinnell, et al., 2011), its abundance was approximately 4-fold 
lower in the rat brain than in triple KO mouse brain (Bmax = 61 +/- 2 fmol/mg) – possibly 
explaining the correspondingly lower analgesic ED50 observed in tail-flick assays 
described above.  
The greater size of the rat brain also permitted the exploration of regional 
binding distribution (Figure 22B). Binding was heterogeneous across regions, with 
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Table 2: Competition studies of [125I]IBNtxA binding in rat brain  
Radioligand competition assays were performed in the presence of mu, delta, and 
kappa1 blockers (250 nM each). Results are the mean ± S.E.M. of at least three 
independent determinations, each performed in triplicate. Hill slopes were determined 
on the binding between 15 and 85% inhibition. A number of compounds showed slopes 
far less than unity, consistent with binding heterogeneity - indicating that their Ki values 
may reflect the cumulative inhibition of multiple sites with differing affinity. In order to 
further address this question, several drugs were examined in greater detail (Figure 23; 
Table 3). The values for the triple KO mouse brain (Majumdar et al., 2011b), calf brain 
(Clark et al., 1989), and human neuroblastoma SK-N-BE(2)-C cell line (Standifer et al., 
1994) are taken from the literature. 
structures such as the cortex, striatum, periacqueductal gray, and brainstem displaying 
moderate binding but thalamus displaying >2-fold increased abundance while 
cerebellum displayed >85% lower levels relative to the brain as a whole.  
Finally, we examined the pharmacology of the labeled site by performing 
competition studies with various drugs (Table 2). As in triple knockout mouse brain 
binding, mu,  delta, and kappa selective drugs exhibited low affinity for the site while  
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Figure 23: Detailed competition studies in rat brain membranes. 
Rat brain homogenate was incubated with [125I]IBNtxA (0.1 nM) with blockers at the 
indicated concentrations of the specified competitor. Nonspecific binding was 
determined using levallorphan (1 mM). Results are pooled from three independent 
replications perfomed in triplicate, each giving similar results, and shown as mean ± 
S.E.M. Each data set was fit with both a one-site and two-site model using GraphPad 
Prism, and the models were compared using an extra-sum-of-squares F-test. The two-
site model was preferred for all four drugs tested (P < 0.0001 for each). 
many opioids previously established as having high affinity for kappa3 site as defined by 
[3H]-NalBzOH binding in calf striatum in the presence of EDTA (Clark et al., 1989) 
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competed binding with moderate to high affinity. Interestingly, buprenorphine showed 
very high affinity for this site in both mouse and rat brain binding. 
Again, although the rat and mouse binding appeared similar overall, there were 
several notable differences across species, such as the significant shifts in competition 
curves of ketocyclazocine, norBNI, levorphanol, and levallorphan. We noticed that the 
hill slopes of many of these compounds tested appeared to deviate significantly from 
unity and therefore selected 4 of the drugs with the shallowest curves for more detailed 
competition studies (Figure 23). These drugs produced competition curves that were 
clearly biphasic, revealing high and low affinity components of their binding (Table 3) 
and suggesting that the target labeled in the rat by 125IBNtxA may not be a single 
homogenous population of receptors.  
 
Table 3: Detailed competition studies for selected opioids on rat brain 125IBNtxA 
binding 
Radioligand competition assays were performed in the presence of mu, delta, and 
kappa1 blockers (250 nM each). Results are mean ± S.E.M. of three independent 
replications perfomed in triplicate, each giving similar results. Each data set was fit with 
both a one-site and two-site model using GraphPad Prism, and the models were 
compared using an extra-sum-of-squares F-test. The two-site model was preferred for 
all four drugs tested (P < 0.0001 for each). 
Discussion 
The quest for the ideal analgesic has consumed decades of research and 
produced thousands of new opioid compounds. Despite substantial advances in our 
understanding of opioid receptor pharmacology, the mainstays of pain management – 
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analgesics targeting the mu opioid receptor such as morphine, fentanyl, and oxycodone 
– still exhibit the same problematic side effect profile of tolerance, dependence, 
constipation, respiratory depression, and euphoria resulting in abuse and addiction. The 
history of opioid pharmacology has been to discover and exploit receptor heterogeneity 
to maximize desired effects while minimizing off-target side effects, splitting “opioid 
receptors” first into mu, delta, and kappa subtypes, and then subtypes of each of these 
receptors defined pharmacologically as reviewed in Chapter 1. Recent efforts have 
focused on agonist bias, whereby drugs may preferentially activate different signaling 
pathways which mediate different effects of drugs (Bohn et al., 2000; Raehal et al., 
2005). Other studies have revealed the existence of homo- and heteromeric signaling 
complexes comprised of multiple GPCRs, which exhibit unique properties from their 
component receptors and may be specifically targeted by drugs (Gomes et al., 2004, 
2013; Jordan & Devi, 1999; Y-X Pan et al., 2002; Yekkirala et al., 2011; Yekkirala, 
Kalyuzhny, & Portoghese, 2010). 
 Our approach has focused on reconciling the pharmacologically defined opioid 
receptor subtypes with the extensive alternative splicing observed for the mu opioid 
receptor gene. Indeed, this focus on splice variants is complementary with research on 
ligand bias and heterooligomerization as different splice variants are likely to interact 
with different complement of proteins to mediate their effects, and their expression is 
known to differ in a regionally and cell-type specific manner (Abbadie, Pan, Drake, & 
Pasternak, 2000; Abbadie et al., 2004). Although truncated 6TM mu receptor variants 
were described over a decade ago, their deviation from the canonical 7TM GPCR 
structure and inability to bind ligands when expressed heterologously called their 
functional relevance into question (Ying-Xian Pan et al., 2001). The generation of an 
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MOR exon 11-knockout animal has definitively established a role for these truncated 
receptors in opioid pharmacology for drugs both new and old. 
 Here, a novel opioid pain reliever, IBNtxA, was shown to exhibit powerful 
analgesia with a vastly superior side effect profile. In both mice and rats, IBNtxA was 
several-fold more potent than morphine in the radiant heat tail-flick assay, and other 
studies have since demonstrated its broad analgesic efficacy in other models of pain 
(Wieskopf et al., 2014). More importantly, however, IBNtxA showed a superior safety 
profile, producing no respiratory depression in either mice or rats. In both rodent 
species, IBNtxA was not cross-tolerant with morphine and also failed to precipitate 
withdrawal in tolerant animals. In mice, IBNtxA continued to show a limited amount of 
constipation, but this off-target effect may be avoided by more selective compounds 
targeting the site labeled by this drug. Importantly, its benign character in a mouse 
conditioned place preference assay suggests low liability for diversion and abuse of the 
drug although future studies will be needed to confirm these findings in other species 
and models of drug reward and reinforcement. 
[125I]IBNtxA binding in the rat brain revealed the regional distribution of the likely 
target producing the drug’s analgesic effects, with highest levels observed in the 
thalamus – a region critically involved in pain pathways (Monconduit, Bourgeais, 
Bernard, Le Bars, & Villanueva, 1999; A. Pert & Yaksh, 1974; Pozza et al., 2010; Zubieta 
et al., 2001). Competition studies in mouse and rat showed low affinity of many 
selective mu, delta, and kappa compounds for the site while other compounds such as 
naloxone benzoylhydrazone, the prototypical “kappa3” drug, exhibited higher affinity, 
suggesting some overlap of this target with the pharmacologically defined kappa3 site 
identified decades ago (Clark et al., 1989). Indeed, naloxone benzoylhydrazone analgesia 
is absent in MOR exon 11-knockout animals, consistent with this identity (Majumdar, 
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Grinnell, et al., 2011). However, the substantially lower Bmax of [125I]IBNtxA versus [3H]-
naloxone benzoylhydrazone in mouse brain suggests that [125I]IBNtxA is labeling only a 
subpopulation of these sites. 
 Despite the widespread similarity between findings in mice and rats, binding was 
notably different between species. Although the affinity for the target in the presence of 
selective mu, delta, and kappa blockers did not significantly differ between species, 
[125I]IBNtxA binding was much lower in the rat brain (Bmax = 15 fmol/mg protein) relative 
to the mouse (Bmax = 60 fmol/mg protein in triple knockout brain). Additionally, although 
trends in competition studies were similar between species, most drugs with high 
affinity against [125I]IBNtxA in triple knockout mouse brain competed [125I]IBNtxA 
binding in rat brain at least an order of magnitude less potently. This may be explained 
in part by the heterogeneity observed in the shallow hill slopes and more detailed 
competition studies which revealed the presence of both very high and low affinity 
components competed by the drugs examined; thus, the “apparent Ki” values reported 
must be interpreted with caution.  
It is unclear what these two sites represent genetically, although the addition of 
250nM mu, delta, and kappa blockers in these assays argues against these traditional 
opioid receptors. Although mu opioid receptor splicing patterns are broadly conserved 
across mouse, rat, and human genomes, the rat MOR-1 splicing produces two isoforms 
of the truncated MOR-1G isoform implicated in IBNtxA analgesia by rescue(Lu, Xu, 
Pasternak, and Pan, accepted manuscript). These isoforms, rMOR-1G1 and rMOR-1G2, 
are homologous with the human isoforms, hMOR-1G1 and hMOR-1G2 which were 
isolated from human brain tissue(Xu, Xu, Hurd, Pasternak, & Pan, 2009). These splice 
variants are also expressed in SK-N-BE(2)C cells, a human neuroblastoma cell line which 
also exhibits [125I]IBNtxA and [3H]-Naloxone benzoylhydrazone binding (Mathis, 
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Mandyam, Altememi, Pasternak, & Standifer, 2001). However, it is unlikely that these 
two isoforms represent the high and low affinity components of [125I]IBNtxA binding in 
rat brain as the 6TM protein products of these genes differ by only 7 amino acids 
(MGSGPML) present at the N-terminus of rMOR-1G2. Another tantalizing possibility is 
that the 6TM isoform forms complexes with multiple other proteins, producing multiple 
active signaling complexes – targets for future attempts at exploiting opioid receptor 
multiplicity toward the ultimate goal of the powerful pain reliever lacking side effects. 
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Chapter 4: Receptor mechanisms of an unusual opioid, 
buprenorphine: Involvement of MOR Exon 11-associated 
Splice Variants 
Introduction 
Buprenorphine was synthesized nearly 50 years ago as one of a large series of 
semi-synthetic opioids referred to as the “Bentley Compounds,” – or, more technically, 
orvinols and thevinols. While at the University of Aberdeen in the early 1960s, 
pioneering opioid organic chemist Kenneth Bentley had begun experimenting with Diels-
Alder adducts of thebaine and oripavine. Shortly thereafter, Bentley was hired by 
pharmaceutical research and manufacturing firm McFarlan Smith, assembling a team of 
medicinal chemists in a joint research program with British consumer product 
manufacturer Rickett & Colman3 which would famously synthesize and test numerous 
semi-synthetic opioid derivatives over the next decade. 
Thebaine and oripavine are morphinan alkaloids occurring naturally in opium 
and poppy straw although at lower concentrations than morphine and codeine, and are 
only moderately potent analgesics on their own. However, using the C-ring of the these 
alkaloids as a diene in a Diels-Alder [4 + 2] addition, a bridged ring system is formed by 
reaction with various dienophiles such as methyl vinyl ketone, leaving behind a new 
ketone which is readily diversified by alkylation with numerous Grignard reagents. 
Subsequent substitutions at the 3-hydroxy and 17-N-methyl positions, and saturations 
of the 7,8-double bond further resulted in thousands new semi-synthetic opioids which 
                                                      
3 Lewis (1999) recollects the peculiar circumstances leading Rickett & Colman, a company whose business 
primarily involved producing grocery products, to fund a major research campaign resulting in the 
production of thousands of novel opioids - some of which were thousands of times more potent than 
morphine. In fact, their initial goal was simply to replace codeine in one of the company’s over-the-
counter formulations of aspirin. 
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were tested for retention of morphine’s analgesic effects but superior side effect 
profiles by Bentley’s research group. 
Early success was achieved with compound M99, named etorphine, which was 
several thousand-fold more potent than morphine in various rodent models of thermal 
and mechanical pain (Bentley & Hardy, 1963; Blane, Boura, Fitzgerald, & Lister, 1967; 
Lister, 1964). However, etorphine suffered essentially the same side effect profile as 
existing mu opioids, and reports that minute quantities had been used to immobilize 
large game such as elephants or rhinocerii quickly caught media attention and inflamed 
the imaginations of regulators fearing a new drug addiction epidemic of “ultra-potent 
heroin.” Thus, although Janssen’s discovery of the similarly super potent analgesic 
fentanyl resulted in enormous commercial success and widespread use today, the 
World Health Organization deemed etorphine too dangerous for humans and it was 
added to the most restrictive list, Schedule 4. Its use is still limited to large animal 
veterinary practice worldwide, although the even more potent 7,8-unsaturated 
derivative dihydroetorphine is used in China as an analgesic and in opioid maintenance 
therapy for the treatment of opioid dependence (Ohmori & Morimoto, 2002; Qin, 
1996). 
Later efforts focused on N-cyclopropylmethyl orvinol derivatives, as this moiety 
was known to produce antagonist effects when substituted on the morphinan 
pharmacophore. Compounds M278 and M285 appeared promising in rodents as potent 
analgesics which did not produce a morphine withdrawal syndrome, but early human 
tests revealed psychotomimetic and dysphoric effects which we now know result from 
their agonist activity at kappa receptors. Another candidate, M5205, showed weak 
activity in humans, some dysphoria, and a morphine-like withdrawal effects in rhesus 
monkeys. The failure of the group to produce a clinically viable product began to 
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concern Rickett & Colman and the group decided to reexamine some of the orvinols 
which had previously been rejected on the basis of rat tail-pressure screening, 
particularly several which exhibited bell-shaped curves in the rat warm water tail-
withdrawal test (Cowan, Lewis, & Macfarlane, 1977; recounted in Lewis, 1999). These 
drugs were found to act as partial agonists, antagonizing morphine effects but also 
capable of producing analgesia when administered on their own, a property the group 
hypothesized would translate into lower abuse potential. Tests of withdrawal 
syndromes in patas monkeys revealed that one of these drugs, M6029, did not display 
either spontaneous or precipitated withdrawal symptoms (Cowan, Lewis, et al., 1977). 
The group selected this drug - later named buprenorphine - to be its final candidate for 
human trials. Several of the group’s chief scientists including John Lewis and Alan Cowan 
were among the first volunteers to receive the drug intravenously, finding it to be 
generally safe and well-tolerated after acute administration, although Lewis suffered 
nausea and vomiting – a notable side effect of the drug shared with other mu 
analgesics. Oral formulations demonstrated low bioavailability but a sublingual 
formulation was successfully developed and carried into clinical trials in post-operative 
pain. 
Alan Cowan studied the pharmacology of buprenorphine in animals extensively 
(Cowan, Doxey, & Harry, 1977; Cowan, Lewis, et al., 1977). In rodents, buprenorphine is 
a potent analgesic with an analgesic ED50 >25-fold lower than that of morphine and a 
considerably longer duration of action. As previously noted, it produces a bell-shaped 
curve in thermal pain models such as warm-water tail-withdrawal and tail flick, with 
doses up to 3 mg/kg showing increasing levels of analgesia and a subsequent 
descending arm observed at higher doses. Tolerance developed to the drug’s analgesic 
effects, albeit more slowly than to morphine, and animals showed cross-tolerance 
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between morphine and buprenorphine. In rodents, low doses of buprenorphine can 
antagonize morphine analgesia, and it precipitates a partial withdrawal syndrome in 
morphine-dependent mice and monkeys but not rats. Importantly, as noted previously, 
monkeys made tolerant to buprenorphine fail to demonstrate a significant withdrawal 
syndrome. 
Buprenorphine also showed a superior side effect profile to morphine, 
particularly with respect to respiratory effects. Although some respiratory depression 
was observed in rats, the drug showed a ceiling effect with increasing doses, and the 
maximal effect on PCO2 was just half that produced by morphine. Accordingly, the 
therapeutic window between analgesic ED50 and LD50 was dramatically improved over 
that of morphine. Furthermore, a bell-shaped curve was seen for inhibition of 
gastrointestinal transit, with doses up to 0.3mg/kg decreasing transit and doses above 
this amount producing decreasing effects to the levels observed in saline controls. The 
effects observed in animals largely mirrored those subsequently observed in humans 
(reviewed in Pergolizzi et al., 2010). In particular, although in vitro assays such as 
stimulation of [35S]-GTPγS binding often show buprenorphine as a partial agonist at mu 
opioid receptors, it appears to be fully efficacious using analgesia in humans as an 
endpoint (Dahan et al., 2006; Raffa et al., 2014); indeed, Pergolizzi and Raffa, et al. go to 
great lengths to clarify that it is impossible to predict based solely on in vitro functional 
assays whether a drug will behave as a full or partial agonist in vivo in a given tissue, 
endpoint, and context (such as dependent vs. nondependent patients). Critically, using 
respiratory depression in humans as an endpoint, buprenorphine truly does manifest 
the properties of a partial agonist, displaying a ceiling effect with maximal inhibition 
significantly lower than other agonists such as morphine and fentanyl (Dahan et al., 
2005, 2006). As in rodent models, this is manifest in a wider therapeutic window 
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between effective dose and toxic/lethal dose, providing an increased margin of safety 
over other more commonly used opioids in clinical practice (Pergolizzi et al., 2010; 
Yassen, Olofsen, Kan, Dahan, & Danhof, 2008). One caveat, however, is that reversal of 
buprenorphine induced respiratory depression requires higher doses of naloxone than 
would be required for other clinically used opioids, and also shows a bell shaped curve 
hinting at the involvement of multiple receptor systems  (Dorp et al., 2006). 
At first glance, buprenorphine shows many similarities with IBNtxA as a powerful 
pain reliever with a superior side effect profile to other opioid analgesics. However, 
despite these improvements, buprenorphine still produces clinically relevant 
constipation, and produces euphoria and drug-liking, especially in non-opioid dependent 
users (Duke, Correia, Walsh, Bigelow, & Strain, 2010; Jones, Madera, & Comer, 2014; 
Middleton, Nuzzo, Lofwall, Moody, & Walsh, 2011). Notably, abuse is seen at lower 
levels relative to conventional opioids - perhaps due to the potential for precipitation of 
withdrawal, either by buprenorphine itself or naltrexone also present in the more 
widely used sublingual formulation, Subutex® (Alho, Sinclair, Vuori, & Holopainen, 2007; 
Cicero & Inciardi, 2005). Intriguingly, while buprenorphine analgesia is lost in knockout 
animals lacking exon-2 associated variants of the mu opioid receptor, potentiation of 
analgesia by an ORL1 antagonist, J-113397 and in ORL1 knockout animals points to as yet 
unappreciated receptor mechanisms mediating buprenorphine’s effects (Lutfy et al., 
2003). Other studies have suggested multiple sites of action for buprenorphine 
analgesia, with spinal analgesia blocked by naloxone but supraspinal analgesia 
appearing naloxone-insensitive (Ding & Raffa, 2009).  Additionally, buprenorphine 
shows analgesic cross-tolerance with naloxone benzoylhydrazone, the prototypical 
kappa3 agonist (Pick, Peter, Schreiber, & Weizman, 1997), and competes [125I]-IBNtxA 
binding with high affinity in binding assays in triple opioid knockout mouse brain, as well 
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as mouse or rat brain in the presence of mu, delta, and kappa blockers (Grinnell et al., 
2014; Majumdar, Grinnell, et al., 2011). We therefore sought to examine the role of 
exon 11-associated and exon 1-associated MOR splice variants in buprenorphine’s 
effects. 
Results 
As discussed previously, some mu opioids such as morphine and methadone, 
lose all analgesia in an MOR exon 1 knockout animal, while drugs like M6G and heroin 
retain full efficacy with only slight loss in potency (A. G. Schuller et al., 1999). MOR Exon 
11 knockout animals display a total loss of analgesia to IBNtxA, and a decrease in 
potency is observed to fentanyl, M6G and heroin, while morphine and methadone 
analgesia are unaffected (Majumdar, Grinnell, et al., 2011; Ying-Xian Pan et al., 2009). 
In tail flick tests, buprenorphine showed a unique pharmacological profile, 
displaying sensitivity to loss of both exon 11- and exon 1-associated MOR variants 
(Figure 24). In wildtype C57 animals buprenorphine was extremely potent, with an 
analgesic ED50 of 0.028 mg/kg, similar to previous reports. Like IBNtxA, buprenorphine 
analgesia appeared essentially inactive in exon 11 knockout animals even at doses >300-
fold greater than the wildtype ED50 (Figure 24A). The picture was more complicated for 
exon 1 knockout animals, where analgesia was observed, plateauing at approximately 
40%. Furthermore, the ED50 for this partial response did not differ significantly from the 
ED50 in wildtype 129/S6 controls. Clearly, multiple receptor mechanisms contribute to 
buprenorphine’s analgesic effects, with full response requiring both exon 1- and exon 
11-associated variants. 
Binding studies have clearly shown that buprenorphine binds to traditional mu 
opioid receptors with high affinity (P Huang, Kehner, Cowan, & Liu-Chen, 2001). We 
therefore attempted to determine, whether buprenorphine was still capable of  
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interacting with full length mu receptors which are still expressed in MOR exon 11 
knockout animals despite loss of analgesic effects (Ying-Xian Pan et al., 2009). Indeed, 
buprenorphine reversed analgesia produced by morphine pretreatment, suggesting that 
the drug still binds mu receptors and appears to compete with morphine for receptor  
A B 
Figure 24: Buprenorphine analgesia in MOR-1 exon 11 and exon 1 knockout mice. 
Mice were injected with escalating doses of buprenorphine and their tail flick latencies 
tested 30 minutes later to generate dose-response curves. Results are pooled from 2 
independent experiments giving similar results and are expressed as mean ± SEM.  (A) 
Buprenorphine analgesia is lost in exon 11 mice. Buprenorphine was a potent analgesic 
in wildtype C57BL/6 mice (n = 9), with an ED50 value 0.028 mg/kg (0.015 – 0.051), while 
in MOR exon 11-knockout animals (n = 20) it showed only a slight elevation over 
baseline latency. There was a significant difference between curves (p<0.0001, Extra 
sum-of-squares F test).   (B)  Buprenorphine analgesia is significantly reduced in MOR 
exon 1 and triple KO mice. Buprenorphine was also a potent analgesic in wildtype 129S6 
mice (n = 20-24) with an ED50 value of 0.079 mg/kg (0.048 – 0.13). In MOR exon 1 KO (n 
= 12) and triple KO (n = 7-11) mice, buprenorphine appeared to be a partial agonist with 
a maximal effect of approximately 40% of MPE. For these curves, the ED50 values were 
0.064 mg/kg (0.011 – 0.37) for the MOR exon 1 KO and 0.067 mg/kg (0.017 – 0.26) for 
the triple KO. There was no significant difference between dose response curves for 
MOR exon 1 and triple KO animals, and no significant difference for  ED50 values 
between all 3 genotypes, but a significant difference was observed for maximal effect 
(p<0.0001; Extra sum-of-squares F test). 
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 Figure 25: Buprenorphine reversal of morphine analgesia in MOR Exon 11 knockout 
animals.  
Animals were given morphine (10 mg/kg) and their tail flick latencies tested 30 minutes 
later at peak effect. Animals were assessed quantally as a doubling or greater of 
baseline latency, and analgesic animals were randomly assigned to receive either saline 
or buprenorphine (10 mg/kg). 15 minutes after receiving the second injection, animals 
were retested in the tail flick test. Buprenorphine significantly decreased morphine 
analgesia relative to saline control (*, p<0.003, 2-tailed t-test). Results are pooled from 
2 independent experiments with similar results and are expressed as mean ± SEM. 
occupancy, but curiously fails to produce analgesia in the absence of exon 11-associated 
MOR variants. 
Buprenorphine binds opioid receptors relatively nonselectively. We next sought 
to determine whether other DOR, KOR, or ORL1 receptors contributed to the curious 
pharmacological profile observed in Exon 1 and Exon 11 knockout animals. However, 
there was no difference between dose response curves between any individual KOR or 
ORL1 knockout and wildtype 129S6 controls, and the triple opioid receptor knockout 
generated by crossing MOR exon 1 knockout animals with DOR-1 and KOR-1 knockout 
animals appeared no different from MOR exon 1 knockout alone, displaying analgesia 
which plateaued at approximately 40% response (%MPE) with an ED50 for this partial 
response indistinguishable from the MOR exon 1 knockout and wildtype ED50. Taken  
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Figure 26: Buprenorphine analgesia in DOR, KOR, ORL-1, and triple opioid receptor 
knockout mice  
Mice were injected with escalating doses of buprenorphine and their tail flick latencies 
tested 30 minutes later to generate dose-response curves. DOR-1, KOR-1, and ORL-1 
knockout animals did display any difference from wildtype 129S6 controls, while a 
triple opioid receptor knockout animal lacking MOR exon 1 reached a plateau at 30% of 
animals displaying at least a doubling of baseline latency, which did not differ from 
MOR exon 1 knockout alone (Extra sum-of-squares F test). 
together, these studies suggest that buprenorphine analgesia is mediated exclusively via 
mu opioid receptors, consistent with previous findings in MOR exon 2 knockout animals 
(Lutfy et al., 2003). 
 The most definitive demonstration of the involvement of exon 11-associated 
MOR splice variants came via a rescue experiment, where a lentiviral construct was used 
to restore expression of mMOR-1G, one of the truncated 6TM receptors lost in exon 11 
knockout animals. In exon 1/exon 11 double knockout animals which express no 
remaining mu receptor splice variants, lentiviral mMOR-1G was able to rescue IBNtxA 
but not buprenorphine analgesia, consistent with findings herein that buprenorphine 
requires both exon 11 and exon 1 variants for full activity (Lu et al., 2015). However, 
when given either i.c.v. or i.t. to exon 11 knockout animals, lentiviral mMOR-1G 
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Figure 27: Rescue of buprenorphine analgesia by lentiviral delivery of MOR-1G in MOR 
E11 Knockout.  
A lentivirus expressing EGFP and mMOR-1G or EGFP alone (vector) was injected and 
tested for analgesia by buprenorphine given systemically (1 mg/kg, s.c.) at least 5 weeks 
later. (A) Intrathecal lentivirus:  Buprenorphine analgesia was significantly lowered in 
the E11 KO relative to wildtype controls, consistent with results in dose-response 
studies (Figure 24A). There was no effect of vector lentivirus treatment in knockout 
animals, but mMOR-1G lentivirus rescued buprenorphine analgesia relative to both E11 
KO and E11 KO animals treated with vector lentirus. There was no significant difference 
between analgesia in wildtype mice vs E11 KO mice treated with mMOR-1G lentivirus. 
(Bonferroni multiple comparison post-hoc test following one-way ANOVA). (B) 
Intracerebroventricular lentivirus: Buprenorphine analgesia was significantly lowered in 
the E11 KO relative to wildtype controls, consistent with results in dose-response 
studies (Figure 24A). There was no significant difference between analgesia in wildtype 
mice vs E11 KO treated with mMOR-1G lentivirus. (Bonferroni multiple comparison 
post-hoc test following one-way ANOVA). 
rescued systemic buprenorphine analgesia to levels indistinguishable from wildtype 
controls, strongly implicating 6TM variants in the  analgesic effects of buprenorphine. 
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Figure 28: Effect of buprenorphine on locomotor behavior in MOR Exon 11 KO mice. 
Animals (n = 7 for each group) were injected with saline or buprenorphine (3 mg/kg 
s.c.), and their locomotor behavior recorded in an open field activity chamber for 60 
minutes post-injection. Results are mean ± SEM. (A) Total distance traveled during the 
60 min session was significantly increased by buprenorphine injection in both genotypes 
relative to saline vehicle control (p < 0.0001 for a main effect of drug, 2-way repeated 
measures ANOVA; p<0.001 for C57 and p<0.0001 for E11KO, post-hoc Tukey’s multiple 
comparisons test); however, there was no difference between genotypes for either 
saline or buprenorphine injection (p = 0.39 for a main effect of genotype, p = 0.12 for 
drug x genotype interaction; p = 0.95 for saline comparison, p = 0.31 for buprenorphine 
comparison).   (B) Time course of locomotor activity, 5 minute intervals. Within 10 
minutes post-injection, buprenorphine significantly increased locomotor behavior in 
both MOR exon 11 knockout animals and wildtype C57 controls (p < 0.001 for each 
point minutes 10-60; post-hoc Tukey’s multiple comparisons test). There was no 
significant difference between genotypes at any time point for either saline or 
buprenorphine condition. 
We next assessed the role of exon 11-associated splice variants with 
buprenorphine’s side effects to determine whether the same targets mediate both the 
desirable and undesireable effects of the drug. First, we looked at stimulation of 
locomotor activity. Although not a direct measure of reward, opioid-induced locomotor 
stimulation is mediated by disinhibition of dopamine release in the mesolimbic 
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dopamine pathway, the common pathway shared by drugs of abuse (Johnson & North, 
1992; Joyce & Iversen, 1979; Urs, Daigle, & Caron, 2011).  
Administration of a 3 mg/kg dose of buprenorphine produced a robust increase 
in locomotor activity in MOR Exon 11 knockout animals despite the fact that this dose 
did not produce a significant analgesic response in the tail flick assay. There was also no 
significant difference between MOR exon 11 KO animals either in response to saline or 
to buprenorphine, and no difference in time course to either treatment.  
Next, we looked at inhibition of gastrointestinal transit, a model of constipation 
which can be a dose-limiting side effect of opioid analgesics including buprenorphine. In 
this assay, pretreatment with a moderate dose of 0.3 mg/kg buprenorphine produced 
robust inhibition of transit relative to either C57 or Exon 11 KO animals pretreated with 
saline. GI transit appeared higher in Exon 11 knockout animals, although this didn’t 
reach significance, raising the question of whether Exon 11-associated variants might 
actually be involved tonically in the modulation of gut motility. Further studies with 
greater statistical power will be required to answer this question. Taken together, these 
studies suggest that the receptor mechanisms responsible for disinhibition of 
mesolimbic dopamine release and inhibition of gastrointestinal transit are not 
dependent on exon 11-associated variants and that these effects are dissociable from 
the analgesic actions of the drug. 
In vitro functional assays were largely consistent with previous reports on the 
pharmacology of buprenorphine (Figure 30). In our hands, however, buprenorphine 
behaved as a full agonist in CHO cells stably expressing mMOR-1 - contrary to its 
widespread characterization as a partial agonist in this assay (Romero et al., 1999; 
Selley, Sim, Xiao, Liu, & Childers, 1997). Differences between our results and those  
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Figure 29: Effect of Buprenorphine on GI transit in MOR Exon 11 Knockout animals. 
Exon 11 knockout mice (n = 7 per group) or wildtype C57 controls (n = 6) were injected 
with either saline or buprenorphine (0.3 mg/kg s.c.) and 10 minutes later given a 
charcoal meal by gavage. 30 minutes after administration of the charcoal meal, animals 
were sacrificed by cervical dislocation and the distance travelled by the charcoal meal 
was measured as a fraction of the total distance from the pyloric sphincter to the 
cecum. Buprenorphine significantly decreased gastrointestinal motility relative to both 
saline-treated Exon 11 knockout controls (p < 0.0001, post-hoc Bonferroni multiple 
comparisons test following 1-way ANOVA) and saline-treated wildtype C57 controls (p 
< 0.01).  Results are mean ± SEM. 
reported in the literature can be readily explained by the use of different clones of CHO-
MOR stable cells generated in each lab. Differences in receptor expression levels and G-
protein stoichiometry will have profound effects on the maximal stimulation obtained in 
response to both experimental drugs as well as the reference full agonist (DAMGO). 
Specifically, nonlinearity due to ceiling effects may result in partial agonists appearing as 
full agonists. Alone, buprenorphine acted as a relatively neutral antagonist and inverse 
agonist in mDOR and mKOR expressing cells, respectively. Consistent with this 
characterization, buprenorphine potently reversed stimulation produced by DPDPE or 
U50,488.It was also clear that functional assays in heterologously expressing cell lines 
did not match the effects observed in brain tissue. Buprenorphine produced virtually no  
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Figure 30: Effect of buprenorphine on 35S-GTPγS binding in cell lines.  
35S-GTPγS binding assays were performed with membrane homogenates from CHO 
cells stably expressing the indicated opioid receptor. Results are pooled from 3 
independent replications and are expressed as mean ± SEM.  (A) At MOR-1, 
buprenorphine acted as a full agonist relative to 1uM DAMGO control with an EC50 of 
1.8nM (1.3, 2.3). (B) At DOR-1, buprenorphine produced little or no stimulation of 35S-
GTPγS binding above basal levels, and (C) potently antagonized 1uM DPDPE stimulation. 
(D) At KOR-1, buprenorphine behaved as an inverse agonist, potently reducing 35S-
GTPγS binding more than 50% below basal levels (IC50 = 0.36 nM [0.11. 1.4]) and (E) 
reversed stimulation produced by 1uM U50,488 (IC50  = 0.69 nM) with higher 
concentrations further reducing binding below basal levels.
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Figure 31: Effect of buprenorphine on 35S-GTPγS binding in C57 mouse brain. 
35S-GTPγS binding assays were performed with membrane homogenate from C57 
mouse brain. Although DAMGO stimulated 35S-GTPγS binding, buprenorphine did not 
appear active concentrations up to 100nM, a concentration which produced near-
maximal effects in cell lines. The addition of CTAP failed to unmask any inverse agonist 
effect produced by kappa opioid receptors, although it substantially lowered DAMGO 
stimulation. Results are pooled from 5 independent replicates, each showing similar 
results, and are expressed as mean ± SEM. 
stimulation of 35S-GTPγS binding in mouse brain homogenate despite its robust 
stimulation in mMOR expressing cell lines and the ability of DAMGO to stimulate 35S-
GTPγS binding in the same tissue. These results could not be explained by a summation 
of agonist and inverse agonist effects at different receptors as addition of CTAP failed to 
unmask inverse agonist effects as would be predicted by blocking mu receptors alone. 
This data is consistent with previous reports (Romero et al., 1999), and points to the 
limits of simplistic in vitro models of complex opioid receptor pharmacology in vivo, 
especially for a drug which is known to require multiple splice variants of mu receptors 
to produce maximal effects. Unfortunately, the failure of buprenorphine to stimulate 
35S-GTPγS binding even in wildtype brain homogenate precluded any comparison of 
differences in MOR exon 11 knockout brain.  
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Figure 32: Effect of buprenorphine on recruitment of β-arrestin-2.  
(A) Buprenorphine failed to stimulate recruitment of β-arrestin-2 up to 10 µM 
concentrations in a PathHunter assay, despite robust recruitment by 1uM DAMGO. (B) 
Buprenorphine potently antagonized the β-arrestin-2 recruitment produced by a fixed 
dose of 1µM DAMGO with an IC50 of 1.1 nM. Results are pooled from at least 2 
independent experiments with similar results, and are expressed as mean ± SEM. 
Finally, we sought to elaborate on previous investigations of buprenorphine’s G-
protein independent signaling via recruitment of β-arrestin-2 (McPherson et al., 2010). 
Biased agonists which preferentially activate G-protein signaling pathways have been 
suggested as superior pain relievers lacking side effects associated with arrestin 
signaling. Indeed, Phase II clinical trials are in progress with a G-protein biased mu 
opioid receptor agonist (TRV-130) for treatment of severe pain with a superior side 
effect profile such as decreased depression of respiration. If this hypothesis is correct, 
buprenorphine is the perfect biased agonist, with high potency in the 35S-GTPγS assay 
and no detectable stimulation of β-arrestin-2 recruitment at concentrations of up to 
10µM. In fact, buprenorphine potently antagonized β-arrestin-2 recruitment by DAMGO 
with an IC50 of just 1.1 nM.  
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Discussion 
 The development of a powerful pain reliever with an improved side effect profile 
over currently used opioid analgesics is the ultimate goal of opioid pharmacology 
research and decades of medicinal chemistry efforts. Indeed, with buprenorphine, that 
goal appears to have been partially realized, yet buprenorphine is still not commonly 
used by clinicians in the United States for the treatment of moderate to severe pain. 
This situation appears to be changing as buprenorphine’s unique properties achieve 
more widespread appreciation and misconceptions are dispelled about its mu partial 
agonist classification in in vitro assays versus full agonist activity in humans with pain 
relief as an endpoint. Critically, recent studies have supported an additional role for 
buprenorphine’s inverse agonism at kappa receptors in the treatment of anxiety and 
depression and in combating relapse in opioid and cocaine addicts (Cordery et al., 2014; 
Sorge, Rajabi, & Stewart, 2005; Wee, Vendruscolo, Misra, Schlosburg, & Koob, 2012). 
  This study examined the contribution of mu opioid receptor splice variants to 
the analgesic as well as the remaining side effects of buprenorphine. Consistent with 
previous findings, buprenorphine’s analgesia is entirely mu receptor dependent, as exon 
1/exon 11 double knockout animals show no analgesic response while DOR and KOR 
knockout animals show no difference from wildtype controls. Additionally, 
buprenorphine’s analgesia is entirely MOR exon 11-dependent, as doses >300-fold 
higher than the analgesic ED50 in wildtype animals did not produce an analgesic 
response in the tail-flick test. Interestingly, exon 1-associated variants of the mu 
receptor are required for full analgesic response, as both MOR exon 1 and Triple opioid 
receptor knockout animals lacking exon 1-associated variants but retaining exon 11-
associated variants produced a partial response plateauing at ~40% MPE. 
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Despite failing to produce an appreciable analgesic response in exon 11-
knockout animals, buprenorphine’s ability to antagonize morphine analgesia is 
consistent with its competition for the traditional mu opioid receptor sites mediating 
morphine analgesia. This model is conceptually similar to the as-yet unexplained finding 
that IBNtxA appears to bind traditional mu opioid receptors and acts as an agonist in 35S-
GTPγS assays in cell lines stably expressing mMOR-1 receptors yet fails to produce 
analgesia in exon 11-knockout animals. An alternate explanation could involve 
buprenorphine activating anti-analgesic or pro-nociceptive pathways, an effect 
mediated by ORL1 receptors and believed to be responsible for the bell-shaped dose 
response curve observed with high doses of buprenorphine (Lutfy et al., 2003). 
Indeed, the 35S-GTPγS studies here are a cautionary tale for over-interpretation 
of the predictive value of in vitro data. In our hands, buprenorphine appeared to act as a 
full agonist in cell lines stably expressing mMOR-1 receptors, while others have reported 
observing lower efficacy (Romero et al., 1999; Selley et al., 1997). These differences may 
be easily explained by the differences in receptor number and G-protein expression 
levels between labs, especially as clonal populations are generally selected on the basis 
of opioid radioligand binding levels with no regard for levels of other proteins involved 
in signaling. Even within a clonal cell population, passage number and differences in cell 
culture technique and conditions can lead to significant differences in these parameters 
within a single lab. However, previous reports are in agreement with our findings that 
stimulation of 35S-GTPγS binding is virtually absent in brain tissue despite its easily 
observed stimulation in cell lines. Although this has been hypothesized to reflect 
considerably lower receptor density in brain tissue relative to heterologously expressing 
cell lines, buprenorphine failed to appreciably stimulate35S-GTPγS binding even in mu 
opioid receptor dense regions such as striasomal patches in the striatum and 
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antagonized morphine stimulation of 35S-GTPγS binding as potently as the full 
antagonist CTAP (Romero et al., 1999). We submit an alternate explanation on the basis 
of our in vivo data - that these results are perfectly consistent with a model in which 
buprenorphine analgesia is mediated via a seperate, MOR exon 11-associated target, 
but acts as a weak partial agonist at the MOR exon 1-associated site mediating 
morphine’s analgesia. 
  On the surface, there are many similarities between IBNtxA and buprenorphine - 
indeed buprenorphine exhibited very high affinity for the site labeled by [125I]IBNtxA in 
both triple knockout mouse and rat brain. It is therefore tempting to speculate that the 
partial analgesic response observed in MOR exon 1 and Triple Knockout Mice is 
mediated by the same receptor as IBNtxA. However, buprenorphine clearly differs from 
IBNtxA in that full analgesic response does require exon 1-associated variants. However, 
the loss of analgesia observed in MOR exon 11-knockout animals clearly differentiates 
this MOR exon 1-dependent target from that mediating the effects of morphine and 
methadone, which retain full analgesic efficacy in MOR exon 11-knockout animals. On 
the basis of these studies, we hypothesize the existence of at least 3 separate mu opioid 
targets: Exon 1-dependent, Exon 11-dependent, and Exon 1- and 11- dependent. 
 Critically, buprenorphine, although displaying a superior safety profile with 
regard to its respiratory depressant effects, still produces constipation – a frequently 
dose-limiting side effect of clinically used mu analgesics (Reimer et al., 2008). Despite 
loss of analgesia, MOR Exon 11-knockout animals continue to show inhibition of GI 
transit following buprenorphine administration, suggesting that this side effect is not 
mediated by the same target as that producing analgesia. The locomotor stimulating 
effects were also completely intact, suggesting that buprenorphine’s disinhibition of 
mesolimbic dopamine release was also mediated independently of its analgesia. As the 
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common pathway by which drugs of abuse produce reward, these findings support 
further investigation using conditioned place preference or self-administration in order 
to determine whether exon 11-associated variants also dissociate buprenorphine 
analgesia from reward. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
87 
 
Chapter 5: Kappa1, and Alpha2-adrenergic receptor 
agonists require truncated 6-transmembrane variants of 
the mu opioid receptor for analgesia but not side effects 
Introduction 
Achieving the goal of powerful pain relief without side effects has led many 
researchers to abandon mu opioids altogether, rather than pursuing a strategy of 
subtype selectivity. Early promise was seen with what we now know are full agonists at 
kappa1 opioid receptors such as nalorphine – however, tests in humans showed they 
had their own significant side effects such as psychotomimesis and dysphoria (Cahal, 
1957; Kumor et al., 1986). While partial kappa agonists show a reduced incidence of 
these side effects, their use is a dwarfed by that of traditional mu agonists like 
morphine, fentanyl, oxycodone, and hydrocodone. 
Alpha2 adrenergic agonists such as xylazine are widely used in veterinary 
analgesia, while clonidine and especially dexmedetomidine are increasingly used for 
their sedative and analgesic properties in surgical and intensive care settings. Systematic 
review and meta-analysis of randomized, placebo controlled trials of clonidine or 
dexmedetomine administered to surgical patients found that alpha2 agonist treatment 
decreased post-operative pain intensity, lowered opioid consumption, and decreased 
incidence of opioid-related adverse events such as nausea (Blaudszun, Lysakowski, Elia, 
& Tramèr, 2012). Paul and Tran showed analgesic crosstolerance between clonidine and 
nalorphine, a kappa3 opioid agonist which we previously showed to require exon 11-
associated MOR splice variants for full analgesic potency (Majumdar, Grinnell, et al., 
2011; Paul & Tran, 1995). Analgesic synergy between the alpha2 adrenergic system and 
the opioid system has been studied in depth (for a recent review, see Chabot-Doré, 
Schuster, Stone, & Wilcox, 2014). Synergy is believed to occur on multiple levels, with 
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interactions occurring by direct physical interactions between receptors (Vilardaga et 
al., 2008) as well as N- and P-type calcium channels and Protein Kinase C, but not 
Protein Kinase A (Roerig & Howse, 1996; Wei, Karim, & Roerig, 1996; Wei & Roerig, 
1998). 
As with the alpha2-adrenergic receptors, opioid-cannabinoid system crosstalk 
has been well established (for a recent review, see Katia, 2015). These interactions are 
also believed to occur at multiple levels, including via intracellular messengers, 
downstream release of endogenous ligands, and possibly even direct protein-protein 
interactions. Cannabinoids such as Δ9-tetrahydrocannabinol and nabilone, as well as 
Cannabis sativa itself, are used to treat pain, either alone or in combination with opioid 
pain relievers, although their abuse potential and significant effects on cognition also 
limit their use. Still, increasingly relaxed state laws and federal enforcement have led to 
a dramatic increase in patients using cannabis for the treatment of pain and countless 
other indications in the last decade – a trend that seems unlikely to reverse in the 
forseeable future. 
Following our unexpected findings that buprenorphine analgesia was totally lost 
in MOR exon 11 knockout animals, we questioned whether other established classes of 
analgesics, opioid and non-opioid alike, might also unexpectedly require MOR exon 11-
associated splice variants.  
Results 
Effect of MOR exon 11 knockout on kappa1 opioid agonist behavioral pharmacology 
 In wildtype C57Bl/6 animals, the prototypical kappa1-selective agonist U50,488 
was a potent analgesic when administered systemically, supraspinally, or spinally (Figure 
33A-C).  However, we observed a dramatic loss in analgesic potency in MOR exon 11 
knockouts, with animals failing to demonstrate even 25% response at doses greater  
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Figure 33:  Effect of MOR exon 11 knockout on U50,488H analgesia.  
Wildtype C57BL/6 (C57) or MOR exon 11 knockout (E11 KO) mice were injected via the 
indicated route with escalating doses of U50,488H and tested using a radiant heat tail 
flick assay at peak effect. Results are mean ± SEM from at least 2 independent 
experiments, each producing similar results. (A) Subcutaneous injection (n = 10-19 for 
each group): ED50 values (95% confidence limits) were 1.7 mg/kg (1.1 – 2.6) for C57. No 
reliable ED50 could be obtained for the E11 KO group, but there was a significant 
difference between genotypes (p < 0.0001 for a main effect of genotype, 2-way ANOVA; 
p < 0.05 at 1 mg/kg dose and p < 0.0001 for 5, 10, and 20 mg/kg doses, post-hoc 
Bonferroni multiple comparison test). (B) Intracerebroventricular injection (i.c.v., n = 9 
for C57, n = 7 for E11 KO): The ED50 for C57 animals (95% confidence limits) was 1.5 ug 
(0.76 – 2.9). However, E11 KO animals failed to display any significant response doses 
>13-fold higher than the wildtype ED50. At the highest dose tested in wildtype animals, 
there was significantly lower analgesic response in E11 KO animals vs C57 (p = 0.002, t-
test). (C) Intrathecal injection (i.t., n = 5 for each group): The ED50 for C57 animals (95% 
confidence limits) was 5.3 ug (2.4 – 12). It was not possible to determine a reliable ED50 
in E11 KO animals, but there was significantly lower analgesic response in E11 KO 
animals vs C57 (p = 0.0001 for a main effect of genotype, 2-way ANOVA; p < 0.003 at 
5ug dose and p < 0.0001 at 20 ug dose, post-hoc Bonferroni multiple comparisons test). 
than 30-fold higher than the ED50 obtained in wildtype controls when injected 
subcutaneously. Supraspinally, U50,488 analgesia was completely abolished in MOR 
exon 11 knockout animals at doses up to 13-fold greater than the wildtype ED50. 
Spinally, knockout animals failed to reach 25% maximum possible effect at doses 4-fold 
higher than wildtype ED50.   
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 The natural product and neoclerodane diterpene Salvinorin A has also been 
shown to be highly selective for the KOR (Roth et al., 2002), despite its obvious 
structural dissimilarity to either the prototypic selective arylacetamide kappa opioid 
agonists such as U50,488 and U69,593 or the non-selective benzomorphans such as 
ketocyclazocine which originally led Martin to propose the existence of a distinct 
population of “kappa” opioid receptors (Martin et al., 1976). Consistent with the results 
observed for U50,488, we observed a significant loss of Salvinorin A analgesia in MOR 
exon 11 knockout animals relative to wildtype controls (Figure 34), suggesting that the 
results are applicable to the kappa opioid system and are not peculiar to the 
arylacetamide class of kappa agonists. 
 
 
Figure 34: Effect of MOR exon 11 knockout on Salvinorin A analgesia.   
Wildtype C57BL/6 (C57, n = 10) or MOR exon 11 knockout (E11 KO, n = 19, 2 
independent replicates) mice were injected with a  10 mg/kg dose of Salvinorin A and 
tested using a radiant heat tail flick assay 10 minutes later at peak effect. Salvinorin A 
produced modest but significant increase in tail flick latency in C57 animals (p < 0.001 
vs vehicle control in the same animals) but was without significant effect in E11 KO 
animals (p = 0.67 vs vehicle control, One-way ANOVA with post-hoc Tukey multiple 
comparison test). There was a significant difference between C57 and E11 KO analgesic 
response (p < 0.002). 
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Figure 35: Effect of MOR exon 11 knockout on U50,488H conditioned place aversion 
and locomotor behavior.  
(A) E11KO animals (n = 14 for each group) showed a significant aversive response to a 
moderate 5 mg/kg s.c. dose of U50,488 in a conditioned place aversion test (Post-
conditioning vs. pre-conditioning, p < 0.027, Bonferroni multiple comparisons post-hoc 
test after 2-way repeated measures ANOVA). In our apparatus, the response to this 
conditioning/dose in wildtype C57 animals failed to reach significance (p = 0.21). (B) 
There was no difference in U50,488’s depression of wildtype C57 and E11 KO animals’ 
locomotor behavior during any of the 3 drug conditioning sessions relative to morning 
saline control (p = 0.62 for genotype, p = 0.34 for session number, p = 0.40 for 
interaction, 2-way ANOVA). 
The psychotomimetic and aversive effects of kappa opioid agonists have 
substantially limited their development and use as analgesics, and the endogenous 
kappa opioid receptor system has been shown to mediate the aversive effects of stress 
and stress-induced reinstatement of drug seeking, a model of relapse in human addicts 
(Bruchas, Land, & Chavkin, 2010; Land et al., 2009; McLaughlin, Land, Li, Pintar, & 
Chavkin, 2006). We therefore sought to determine whether the aversive effects of a 
selective kappa agonist would also be impaired in MOR exon 11 knockout animals. To 
the contrary, we observed significant conditioned place aversion to U50,488 in knockout  
92 
 
C
57
 W
T
E
xo
n 
11
 K
O
Ex
on
 1
1 
K
O
 +
 
m
M
O
R
1G
 le
nt
iv
ir
us
0
25
50
75
100 ****
*
*
C
57
/1
29
 W
T
Ex
on
 1
/1
1 
K
O
E
xo
n 
1/
11
 K
O
 +
 
m
M
O
R
1G
 le
nt
iv
iru
s
A B
 
Figure 36: Lentiviral mMOR-1G rescue of U50,488H analgesia. 
A lentivirus expressing EGFP and mMOR-1G was injected i.c.v. into MOR Exon 11 KO (A) 
or MOR Exon 1/11 KO (B). U50,488H (20 mg/kg, s.c.) analgesia tested at least 5 weeks 
later. Results are mean ± SEM from at least 2 independent experiments, each showing 
similar results. (A) Consistent with previous findings, Exon 11 KO (n = 10) showed 
significantly impaired analgesic response to a 20 mg/kg dose of U50,488H (p < 0.0001 vs 
C57 WT (n = 9), post-hoc Tukey test following one way ANOVA). Significant analgesic 
efficacy was restored following lentiviral mMOR-1G infection (n = 8, p < 0.05 vs E11KO) 
although analgesia was still reduced relative to wildtype control (p < 0.05). (B) As 
predicted, Exon 1/11 KO (n = 10) showed significantly impaired analgesic response to a 
20 mg/kg dose of U50,488H (p < 0.0005 vs C57/129 WT (n = 8), post-hoc Tukey test 
following one way ANOVA). Analgesic efficacy was fully restored following lentiviral 
mMOR-1G infection (n = 3, p < 0.001 vs E1/E11KO; p = 0.37 vs C57/129 WT). 
animals (p < 0.027) even at a moderate dose of 5 mg/kg s.c. which produced no 
analgesia in knockout animals (Figure 35). Indeed, the difference observed in wildtype 
controls’ post-conditioning preference did not reach significance at this dose in our 
apparatus, confirming that the knockout animals retain equal or greater sensitivity to 
the aversive properties of kappa agonists. We also observed that U50,488 depressed 
locomotor behavior to a similar extent in both genotypes across each of 3 drug-training 
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sessions relative to saline (Figure 36). Together, these results implicate exon 11-
associated variants in the analgesia, but not locomotor depressing or aversive side 
effects of kappa1 opioid agonists.  
Finally, rescue experiments were performed using a mMOR-1G lentivirus (Lu et 
al., 2015), in press). As previously observed, both MOR Exon 11 knockout and MOR Exon 
1/11 Knockout animals showed total loss of analgesia to 20 mg/kg U50,488H, but 
knockout animals infected with mMOR-1G lentivirus showed restored analgesic efficacy, 
suggesting that the truncated 6TM variant mMOR-1G is sufficient to restore kappa1 
opioid analgesia in animals with exon 11 knockout animals with intact KOR receptors. 
 
Effect of MOR exon 11 knockout on alpha2 adrenergic agonist behavioral 
pharmacology 
 We next examined the role of exon 11-associated MOR splice variants in 
alpha2 agonist analgesia (Figure 37). In fact, MOR exon 11 knockout mice showed a 
significant impairment in tail flick analgesia relative to their wildtype controls following 
clonidine administration by multiple routes, although analgesia was not completely lost. 
Systemically, a very steep dose-response curve was observed, with clonidine analgesia 
failed to exceed 20% MPE at >2 times the ED50 in wildtype animals. The difference 
between genotypes was even more evident supraspinally, where a dose >30-fold higher 
than the ED50 in the wildtype C57 animal produced only 23% MPE response. However, 
spinally, there seemed to be some intact analgesic mechanism remaining, although 
approximately 12-fold rightward shift in ED50 was observed. 
We next tested dexmedetomidine, another imidazoline alpha2 adrenergic 
receptor agonist which is more selective for the alpha2a subtype than clonidine (Figure 
38). In wildtype animals it was a very potent analgesic in the tail flick assay, with an ED50  
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Figure 37: Effect of MOR exon 11 knockout on clonidine analgesia.  
Wildtype C57BL/6 (C57) or MOR exon 11 knockout (E11 KO) mice were injected via the 
indicated route with escalating doses of the prototypical Alpha2 adrenergic receptor 
agonist clonidine and tested using a radiant heat tail flick assay 30 minutes later at peak 
effect. Results are mean ± SEM and are the results from at least 2 independent 
experiments, each producing similar results. (A) Subcutaneous injection (n = 5-10 for 
C57, n = 10 for E11KO): ED50 value (95% confidence limits) for C57 animals was 0.30 
mg/kg (0.19 – 0.46). It was not possible to determine a reliable ED50 in E11 KO animals 
at the doses tested, but there was significantly lower analgesic response in E11 KO 
animals vs C57 (p =0.0001 for a main effect of genotype, 2-way ANOVA; p < 0.0001 at 
0.3, 0.5, and 1 mg/kg doses, Bonferroni multiple comparisons post-hoc test). (B) 
Clonidine, intracerebroventricular injection (n = 10 for each group). The ED50 for C57 
animals (95% confidence limits) was 0.84 ug (0.39 – 1.8). It was not possible to 
determine a reliable ED50 in E11 KO animals at the doses tested, but dose response 
curves were significantly different (p < 0.0001, extra sum-of-squares F test). (C) 
Clonidine, intrathecal injection (n = 5 for each group). ED50 values (95% confidence 
limits) were 1.5 ug (0.84 - 2.7) for C57 vs 18 mg/kg (8 - 42) for E11 KO, which were 
significantly different (p < 0.0001, extra sum-of-squares F test). 
(95% CI) of 0.4 mg/kg (0.02 – 0.06). As predicted, analgesia was substantially impaired in 
MOR Exon 11 knockout animals, consistent with a loss of alpha2a-mediated analgesia. 
The sedative properties of alpha2 agonist drugs such as dexmedetomidine are 
often desirable in the surgical and intensive care settings where they are currently 
employed; however, wider use of this class of drugs for the treatment of opioid- 
refractory pain is limited by this same effect outside of a hospital context (Jackson, 
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Wohlt, and Fine 2006). We therefore sought to determine whether the locomotor 
depressant actions of alpha2 agonists were impaired as was analgesia in MOR exon 11 
knockout animals (Figure 39). As with delta and kappa agonists, despite profound loss of 
analgesic potency, a moderate dose of clonidine (0.3 mg/kg s.c.) still significantly 
depressed total distance travelled during a 1 hour session in an open field activity 
chamber in knockout animals as in wildtype C57 controls. Furthermore, there was no 
difference in distance travelled between genotypes following either saline or clonidine, 
and no significant difference was seen between the genotypes’ reaction to either saline 
or clonidine at any time point during the 60 minute session. 
 
Figure 38:  Effect of MOR exon 11 knockout on dexmedetomidine analgesia. 
Wildtype C57BL/6 (C57, n = 9-13) or MOR exon 11 knockout (E11 KO, n = 6-10) mice 
were injected with escalating doses of dexmedetomidine and tested using a radiant 
heat tail flick assay 30 minutes later at peak effect.  Results are mean ± SEM and are 
the results at least 2 independent experiments, each producing similar results. ED50 
value (95% confidence limits) for C57 animals was 0.04 mg/kg (0.02 - 0.06). E11 KO 
response at the 0.1 mg/kg dose was significantly lower than C57 WT ( p < 0.0001, 2-
tailed t-test). 
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Figure 39: Effect of MOR exon 11 knockout on the locomotor depressing effects of 
clonidine.  
Animals were injected with a moderate dose clonidine (0.3 mg/kg, s.c.), and their 
locomotor behavior was recorded for the following 60 min in an open field locomotor 
chamber. Clonidine significantly reduced depressed locomotor behavior relative to 
saline, but there was no difference between each genotype’s response (p < 0.0001 for a 
main effect of drug, p = 0.65 for a main effect of genotype, p = 0.65 for an interaction, 2-
way repeated measures ANOVA;  p < 0.0001 for each genotype’s response to clonidine 
vs. saline, but p > 0.99 for a difference between genotypes for saline and p > 0.98 for a 
difference between genotypes for clonidine, post-hoc Bonferroni multiple comparisons 
test). 
Finally, rescue experiments were performed using the mMOR-1G lentivirus to 
restore expression of a truncated 6TM MOR isoform. As previously observed, both MOR 
Exon 11 knockout and MOR Exon 1/11 Knockout animals showed total loss of analgesia 
to 0.5mg/kg clonidine, and MOR Exon 11 knockout animals infected with mMOR-1G 
lentivirus showed restored analgesic efficacy. Additionally, MOR exon 1/11 animals 
showed an analgesic response that was not significantly different from wildtype, 
although this response narrowly failed to reach significance (p < 0.054) likely due to the  
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Figure 40:  Lentiviral mMOR-1G rescue of clonidine analgesia. 
A lentivirus expressing EGFP and mMOR-1G was injected i.c.v. into MOR Exon 11 KO (A) 
or MOR Exon 1/11 KO (B). U50,488H (20 mg/kg, s.c.) analgesia tested at least 5 weeks 
later. Results are mean ± SEM from at least 2 independent experiments, each showing 
similar results. (A) Consistent with previous findings, Exon 11 KO (n = 10) showed 
significantly impaired analgesic response to a 0.5 mg/kg dose of clonidine (p < 0.01 vs 
C57 WT (n = 10), post-hoc Tukey test following one way ANOVA). Clonidine analgesia 
was fully restored following lentiviral mMOR-1G infection (n = 8, p < 0.05 vs E11KO; p > 
0.99 vs C57 WT) (B) As predicted, Exon 1/11 KO (n = 10) showed significantly impaired 
analgesic response to a 20 mg/kg dose of U50,488H (p < 0.0005 vs C57/129 WT (n = 8), 
post-hoc Tukey test following one way ANOVA). Following lentiviral mMOR-1G infection, 
clonidine analgesia did not differ significantly from C57/129 WT (n = 3, p = 0.27); 
however, it narrowly failed to reach significance relative to MOR E1/E11 KO (p < 0.054 
vs E1/E11KO). 
small number of knockouts (n = 3) available to test. Further experiments will be pursued 
as more animals become available in the future. In total, these results confirm that 
truncated 6TM variants such as mMOR-1G, are required for the expression of alpha2 
adrenergic agonist analgesia. 
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Lack of effect of MOR exon 11 knockout on cannabinoid type 1 agonist analgesia  
Finally, we examined the role of exon 11-associated MOR splice variants in 
Cannabinoid type 1 agonist analgesia. Unlike delta (not shown) and kappa opioid 
agonists or alpha2 adrenergic agonists, however, we did not observe any significant 
difference in analgesic response between MOR exon 11 knockout animals and wildtype 
controls to the selective CB1 agonist CP55,940. In fact, the response was virtually 
indistinguishable between groups, offering a robust negative control and confirmation 
that MOR exon 11 knockout does not produce any form of global deficit in analgesic 
response. 
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Figure 41:  Lack of effect of MOR exon 11 knockout on cannabinoid type 1 agonist 
analgesia. 
Wildtype C57BL/6 (C57) or MOR exon 11 knockout (E11 KO) mice (n = 6-13 for each 
group) were injected s.c. with escalating doses of the prototypical Cannabinoid type 1 
receptor agonist, CP55,940, and tested using a radiant heat tail flick assay 30 minutes 
later at peak effect. Results are mean results of 2 independent experiments, each 
producing similar results. ED50 values (95% CI) were 0.32 (0.20 – 0.52) for C57 WT and 
0.37 (0.21 – 0.66) for E11 KO. There was no significant difference between EC50 values 
between genotype (p = 0.64) 
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Discussion 
Following the unexpected loss of buprenorphine analgesia in MOR exon 11 
knockouts, we examined kappa1, alpha2 adrenergic, and cannabinoid type 1 agonist 
analgesia to determine whether they would also be affected. Indeed, the kappa agonist 
U50,488H showed a complete loss of analgesic efficacy at doses many times higher than 
wildtype ED50 by systemic, supraspinal, or spinal administration. Systemic administration 
of the structurally-unique, non-nitrogenous, and recreationally-used kappa agonist 
Salvinorin A mimicked our findings with U50,488H. Lentiviral delivery of mMOR-1G – a 
6TM splice variant of the mu opioid receptor found in the mouse, rat, and human 
genome – restored analgesic efficacy of U50,488H in two different knockout models, 
confirming the involvement of these isoforms. Critically, the aversive and locomotor 
depressing actions of U50,488H were fully intact in MOR Exon 11 knockout animals, 
suggesting that these effects can be genetically dissociated and that it may be possible 
to design psychologically benign kappa1 analgesics or selectively antagonize kappa-
mediated dysphoria without perturbing pain-related circuits. 
 Similar results were found for the alpha2 adrenergic agonist clonidine, although 
the loss of analgesia appeared to be more pronounced systemically and supraspinally 
than spinally where only a 12-fold shift in analgesia was observed. These results would 
be consistent with loss of alpha2A-mediated analgesia, while at higher doses clonidine 
can interact with alpha2C subtypes present in the spinal cord which are also capable of 
producing analgesia (Fairbanks et al., 2002). Dexmedetomidine analgesia was also lost, 
consistent with the involvement of alpha2A subtypes for which it displays higher 
selectivity. This model could be further tested using alpha2-subtype knockouts as the 
available agonists possess only moderate selectivity for one receptor over another. As 
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with kappa1 receptors, analgesic efficacy was rescued by lentiviral delivery of mMOR-
1G, confirming the involvement of truncated 6TM receptor isoforms. 
Finally, as with U50,488, the locomotor depressing side effects of clonidine were 
fully intact despite loss of analgesic efficacy, dissociating these effects from the 
analgesic effects of this class of drugs. Clonidine has a dramatically different mechanism 
of depressing locomotor activity than U50,488, depressing noradrenergic output from 
the locus ceruleus globally by activating autoreceptors on efferent neurons (Gilsbach et 
al., 2009). Critically, the analgesic effects of clonidine and dexmedetomidine were found 
to be mediated by postsynaptic receptors on non-adrenergic neurons, such as  primary 
nociceptors, in spinal pain relay neurons, and excitatory interneurons in the dorsal horn 
(Pertovaara, 2006). These correlations between location and function may be of 
assistance in assigning the location of the interaction between systems. 
Loss of kappa1 and alpha2 agonist agonist analgesic response is difficult to 
explain for several reasons. No difference in kappa opioid receptor affinity or abundance 
was observed in MOR exon 11 knockout mouse brain with the kappa agonist [3H]-
U69,593 (Pan et al 2009). Kitchen et al found no alteration in kappa affinity or 
expression pattern in the Kieffer lab MOR knockout made by disrupting exons 2, which 
is shared by both 6TM and 7TM isoforms (Kitchen, Slowe, Matthes, & Kieffer, 1997). 
These studies are not necessarily in conflict with our findings, where we can conceive of 
a model whereby the 6TM receptor permits the kappa receptor to signal more 
efficiently or via a different effector pathway, resulting in analgesia. This would further 
explain why analgesia is lost but other effects remain unaffected in the absence of these 
truncated isoforms. The impact of the different MOR-1 knockout models on MOR-1 
splicing has not been systematically studied, so it is impossible to know which splice 
variants would be retained in each animal. 
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More difficult to reconcile are results showing the Kieffer lab exon 2 knockout 
expressed no loss of sensitivity to kappa agonists although delta agonist analgesia was 
diminished (Matthes et al., 1998). Additionally, an MOR exon 2/3 knockout from the Loh 
group showed no analgesic difference from wildtype following administration of the 
alpha2 agonist UK14,304 (Guo, Fairbanks, Stone, & Loh, 2003). The results from these 
dramatically different knockout models appear to be conflicting, however we believe 
the lentiviral rescue experiments in 2 separate knockout models offer compelling 
evidence for an involvement of 6TM receptors. 
Unlike kappa1 and alpha2 agonist analgesia, cannabinoid type 1 agonist analgesia 
appeared totally unaffected by loss of MOR exon 11 splice variants. Indeed, this was a 
welcome development as it argued against a global analgesic deficit and offered a 
much-needed negative control in addition to morphine and methadone. 
Following our unexpected findings with buprenorphine, it was perhaps less 
surprising but all the more exciting that other receptor systems showed a profound loss 
of analgesic response in MOR exon 11 knockout animals. It was even more exciting to 
discover that some of the major side effects which have precluded more widespread use 
of agonists targeting these systems were intact in these animals. Taken together, these 
results suggest that the targets mediating the desired effect – analgesia – are distinct 
and genetically dissociable from the targets mediating major undesired effects of the 
drugs. 
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Chapter 6: Synthesis of Novel Opioid Photoaffinity Labels 
Introduction 
Affinity labeling is a classical biochemical technique which facilitates the 
visualization and identification of the molecular target of a pharmacologically defined 
macromolecular binding site. Early attempts at mapping enzyme active sites successfully 
used small molecules such as phenylmethanesulfonylfluoride (PMSF) to selectively and 
covalently label the catalytic serine of the protease chymotrypsin (Balls & Jansen, 1952). 
However, this approach relied on the exceptional reactivity of this particular serine, 
while other macromolecules such as receptors or antibodies do not possess an 
analogous reactive residue. To this end, the general method of affinity labeling was 
conceived and its usefulness demonstrated using the reactive diazonium fluoroborate 
derivative of a p-nitrophenylarsenate hapten to covalently label the “active site” of a 
rabbit antibody to benzenearsonic acid (Wofsy, Metzger, & Singer, 1962). 
Avram Goldstein’s lab made pioneering attempts at developing a 
photoactivatable affinity label for opioid receptors in 1972 with N-p-(azidophenyl)-
ethylnorlevorphanol; unfortunately, this ligand suffered from high levels of nonspecific 
binding which precluded its successful use. The labs of Portoghese and Takemori were 
more successful with their development a pair of agonist and antagonist alkylating 
agents, chloroxymorphamine and chlornaltrexamine, respectively, which were shown to 
irreversibly label opioid receptors and expressed extremely long-lasting actions in vivo 
consistent with this characterization (Caruso, Takemori, Larson, & Portoghese, 1979; 
Portoghese, Larson, Jiang, Caruso, & Takemori, 1979; Portoghese, Larson, Jiang, 
Takemori, & Caruso, 1978; Takemori, Larson, & Portoghese, 1981). Portoghese’s group 
synthesized another alkylating mu ligand, β-funaltrexamine, which displayed irreversible 
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antagonist activity at mu receptors (Portoghese, Larson, Sayre, Fries, & Takemori, 1980; 
Ward, Portoghese, & Takemori, 1982). This drug would later be used to stabilize the 
antagonist conformation of the mu receptor for crystallization (Manglik et al., 2012).  
[3H]-chlornaltrexamine was used in an attempt to visualize the molecular weight 
of opioid receptor complexes from mouse brain, giving 4 peaks after gel-filtration 
chromatography with 2 running together at a molecular weight of 590 kDa (Caruso, 
Larson, Portoghese, & Takemori, 1980). In contrast, Eric Simon’s group had estimated 
the molecular weight of opioid receptor complexes to be approximately 400 kDa 
following reversible labeling with [3H]-etorphine and purification under native 
conditions (Simon, Hiller, & Edelman, 1975). As we now know the molecular weights of 
mature, glycosylated, monomeric mu, delta, and kappa opioid receptors are in the range 
of 55-75 kDa, it is unclear whether these estimates reflect true signaling complexes, 
receptor homo/heteromers, aggregates, or are simply artefactual. High levels of 
nonspecific incorporation further complicate interpretation, and the tritium radiolabel 
makes monitoring purification difficult, and precludes exposing film following SDS-PAGE. 
Kenner Rice also synthesized several mu- and delta-selective alkylating agents 
derived from fentanyl including (+)-cis-3-methylfentanyl isothiocyanate or “super-FIT” 
(Rice et al., 1983). Using this delta-selective probe, the Klee group was able to isolate 
highly purified delta opioid receptors from NG108-15 cells in a purification scheme 
consisting of affinity labeling, solubilization, wheat germ agglutinin affinity 
chromatography followed by anti-fentanyl immunoaffinity chromatography, and finally 
separation by SDS gel electrophoresis (Simonds, Burke, Rice, Jacobson, & Klee, 1985). 
This scheme revealed a glycosylated band with a molecular weight of approximately 58 
kDa, consistent with the molecular weight of the glycosylated DOR-1 gene product 
which would be discovered 7 years later. Interestingly, Simonds et al note that the 
104 
 
receptor had “a strong tendency to dimerize, even in the presence of denaturing 
detergents, and… exists primarily as an oligomer in nondenaturing detergents.” 
Photoaffinity labeling has the added benefit that the reactive group is not 
exposed until exposure to ultraviolet light, allowing the experimenter to maximize 
receptor occupancy to equilibrium before photolysis and uncaging of an extremely 
reactive intermediate. This minimizes nonspecific labeling by virtue of its high likelihood 
of forming a covalent bond with amino acid residues in the immediate vicinity of the 
group after photoactivation, although in reality some portion of the labeling occurs after 
dissociation and reassociation of the ligand (Ruoho, Kiefer, Roeder, & Singer, 1973). 
Interestingly, no especially reactive group need necessarily be incorporated for UV 
photoactivation, although photolabeling efficiencies may be low as a result; Standifer et 
al were able to photolabel mu, kappa1, or kappa3 receptors using the radioligand [3H]-
naloxone benzoylhydrazone, which contains no traditional photoreactive group at all 
(Standifer, Murthy, Kinouchi, Steele, & Pasternak, 1991). 
The carbene-generating benzophenone and diazirine and nitrene-generating aryl 
azide are the most common photoreactive groups used, each with its own advantages 
and disadvantages such as size, photolabeling efficiency, and reactivity in the absence of 
UV photoactivation. The photochemistry of phenylazide and its phenylnitrene photolysis 
product has been extensively studied (shown in Figure 42; for a thorough review, see 
Gritsan & Platz, 2010). Although the ortho-iodo substituted phenyl azide derivative has 
not been studied as extensively, the rate constant for the reaction of the para-iodo 
didehydroazepine rearrangement product with diethylamine (a model nucleophile) was 
2 orders of magnitude lower than the unsubstituted parent azide, suggesting that the 
presence of iodine on the ring is likely to adversely affect photolabeling efficiency (Y. Li, 
Kirby, George, Poliakoff, & Schuster, 1988). 
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Figure 42: Photochemistry of phenyl azide 
Following UV photolysis of phenylazide (1), molecular nitrogen is released to yield the 
highly reactive singlet phenylnitrene (13). Below 180K, spin relaxation via intersystem 
crossing (ISC) dominates to form the less reactive triplet nitrene (33), while at room 
temperature in solution rearrangement is preferred, forming the didehydroazepine (5) 
via a benzazirine (4) intermediate. In practice, it is this compound which forms covalent 
adducts (2) in the presence of nucleophiles, such as amines. Reproduced from (Gritsan 
& Platz, 2006). 
Still, we chose the azide group due to its relatively small size and ease of 
synthetic incorporation into the IBNalA structure with the goal of producing a high 
affinity, high-specific activity photoaffinity label to facilitate purification and 
characterization of opioid receptors, including the target of IBNtxA. 
Results 
Two arylazide photoaffinity labels were synthesized by amide bond coupling between 4-
azido-3-iodobenzoic acid and 6-β-naloxonamine (6) or N-propargyl-6-β-
nornaloxonamine (7). Competition assays (Table 4 and Table 5) revealed that the both 6  
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Figure 43: Structures of novel opioid photoaffinity labels. 
 
Table 4: Competition studies of photoaffinity label 6 
Escalating concentrations of 6 were incubated with in the presence of the indicated 
radioligand with membranes prepared from CHO cells stably transfected with each 
respective opioid receptor or triple knockout mouse brain. 
Receptor Membranes Radioligand Ki [95% CI] (nM) 
Mu CHO-MOR 3H-DAMGO 0.20 nM [0.13 – 0.34] 
Delta CHO-DOR 3H-DPDPE 16 nM [11 – 24] 
Kappa CHO-KOR 3H-U69,593 0.26 nM [0.17 - 0.38] 
6TM/E11 Mouse Brain (TKO) 125I-IBNtxA 4.1 [3.5 – 6.4] 
 
 
Table 5: Competition studies of photoaffinity label 7 
Escalating concentrations of 7 were incubated with in the presence of the indicated 
radioligand with membranes prepared from CHO cells stably transfected with each 
respective opioid receptor or triple knockout mouse brain. Results are from 3 
independent replications except for TKO mouse brain which is a single determination, 
and are presented as mean ± SEM. 
Receptor Membranes Radioligand Ki ± SEM (nM) 
Mu CHO-MOR 125I-IBNtxA 0.25 ± 0.12 
Delta CHO-DOR 125I-IBNtxA 3.5 ± 0.40 
Kappa CHO-KOR 125I-IBNtxA 0.92 ± 0.29 
6TM/E11 Mouse Brain (TKO) 125I-IBNtxA 0.89 [0.71-1.1] 
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Figure 44: Saturation Binding Studies. 
 [125I]-6 or [125I]-7 incubated at the indicated concentrations with membrane 
homogenate from cells stably transfected with mMOR-1 or mKOR-1. Curves were fit by 
nonlinear regression using Graphpad Prism. Representative figures are shown. Each 
study was replicated 3 times except for  and mean values for KD ± SEM of 3 independent 
replications were: CHO-MOR (A) 6: KD = 0.027 ± 0.004 nM and (B) 7: KD = 0.051 ± 0.013 
nM. For CHO-KOR (C) 6: KD = 0.053 ± 0.002 nM (D) 7: KD = 0.056 ± 0.001 nM. 
and 7 had moderate affinity for delta opioid receptors, and subnanomolar affinity for 
mu and kappa receptors suggesting the drugs could be useful for their desired purpose. 
Following these initial promising findings, the corresponding radioiodination 
precursors were then prepared by coupling 4-azido-3-tributyltinbenzoic acid with 6-β-
naloxonamine (8) or N-propargyl-6-β-nornaloxonamine (9). All structures and compound 
purity were confirmed by TLC, NMR, and LC/MS.  
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Reaction of the tributyltin precursors with chloramine T and Na125I and 
subsequent semi-preparative purification by reverse phase HPLC afforded [125I]-6 and 
[125I]-7. Saturation studies in CHO cells stably expressing mMOR-1 or mKOR-1 receptors 
revealed that the compounds even exhibited higher affinity for mu and kappa receptors 
than predicted based on competiton assays, with KD values of [125I]-6 for mu of 0.027 ± 
0.004 nM and 0.053 ± 0.002 nM at kappa; KD values of [125I]-7 were about 2-fold lower 
for mu at 0.051 ± 0.013 nM although kappa affinity appeared relatively unchanged at KD 
= 0.056 ± 0.001 nM. 
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Figure 45: Dissociation studies of [125I]-6 
[125I]-6 was incubated with CHO-MOR membranes at a concentration of 0.1 nM for 1.5 
hours at 25C to reach equilibrium binding. 10uM levallorphan was then added at the 
indicated time points (5 – 240 min) to determine the kinetics of drug dissociation. 
Results shown are pooled from 3 independent replicates with similar results and are 
expressed as mean [95% confidence intervals]. At 25C, data was best fit by a 2-phase 
exponential decay model (p<0.0001 vs 1-phase decay model, Extra sum of squares F-
test), with 53% [51 – 56] dissociating rapidly and the remainder very slowly.  t1/2 Fast = 
4.6 min [4.1 – 5.2 min], t1/2 Slow = 81 min [75 – 89 min]. At 0C, the dissociation was 
slowed to t1/2 Fast = 14 min [10 – 23 min] and t1/2 Slow = 244 min [207 – 299 min]. 
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More detailed dissociation studies were undertaken for [125I]-6 (Figure 45, 
revealing the presence of both fast and slowly dissociating components with halflives of 
dissociation of t1/2 Fast = 4.6 min [4.1 – 5.2 min], t1/2 Slow = 81 min [75 – 89 min] 
respectively at room temperature, which slowed markedly to t1/2 Fast = 14 min [10 – 23 
min] and t1/2 Slow = 244 min [207 – 299 min] in an ice-water bath. As high affinity binding 
was abolished by GppNHp and sodium, the slowly dissociating site is consistent with 
binding to the agonist conformation of the mu receptor while the quickly dissociating 
site appears to correspond to binding of the antagonist conformation of the receptor.  
After extensive optimization, protocols for photoaffinity labeling different tissues 
were developed. First efforts focused on mu receptors stably expressed by the CHO-
MOR cell line (Figure 46A, Figure 47A). Following photolabeling, the labeled species ran 
as a diffuse band of approximately 68-75 kDa, consistent with the molecular weight of 
the mature, glycosylated form of the murine mu opioid receptor expressed on the cell 
surface, with no bands observed at the molecular weight of the unglycosylated, 
immature forms of the receptor, demonstrating one significant advantage in detection 
and quantitation of the photolabels. Levallorphan blocked receptor labeling, further 
confirming the identity of the photolabeled species and western blot with an MOR  
antibody confirmed that mu opioid receptor protein was present in both lanes (Figure 
47B). Furthermore, cleavage of N-linked sugars from the receptor with PNGaseF yielded 
a photolabeled species with the predicted molecular weight of the mu receptor’s amino 
acid sequence alone, 44kDa (Figure 47C). 
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Figure 46. Photoaffinity labeling with [125I]-6 in CHO-MOR, CHO-KOR, and Mouse 
Brain.  
The indicated tissues were photolabeled with [125I]-6 and separated by SDS-PAGE. All 
autoradiograms are representative and have been independently replicated at least 
twice. T, Total; NS, Nonspecific. (A) CHO-MOR. The photolabeled species ran as a diffuse 
band of approximately 68-75 kDa, consistent with the molecular weight of the mature, 
glycosylated form of the murine mu opioid receptor. (B) CHO-KOR. KOR was enriched by 
wheat germ affinity purification. The photolabeled species ran as a diffuse band of 
approximately 50-57 kDa, consistent with the mature, glycosylated form of murine 
kappa opioid receptor. (C) CD1 Mouse Brain. Mu opioid receptors in mouse brain were 
photolabeled and purified by immunoprecipitation with an antibody to the C-terminal 
region of the receptor. running with lower apparent molecular weight than observed in 
cell lines, approximately 60-65 kDa. 
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Figure 47. Photoaffinity labeling with [125I]-7 in CHO-MOR, CHO-KOR, SK-N-BE(2)C, and 
Mouse Brain.  
The indicated tissues were photolabeled with [125I]-6 and separated by SDS-PAGE. All 
autoradiograms are representative and have been independently replicated at least 
twice. T, Total; NS, Nonspecific. (A) CHO-MOR  Photolabeled mu receptors ran as a 
diffuse band of approximately 68-75 kDa. (B) MOR Western Blot. Probing membrane 
from (A) with MOR antibody confirmed the presence of mu receptors in both Total and 
Nonspecific lanes. (C) PNGaseF. Deglycosylation with PNGase F reduced the molecular 
weight to the predicted molecular weight of 44 kDa. (D) CHO-KOR. Following Wheat 
Germ affinity enrichment,  photolabeled kappa opioid receptors ran as a diffuse band 
from 50-57 kDa. (E) SK-N-BE(2)C neuroblastoma. Mu opioid receptors were 
photolabeled in a natively-expressing cell line, appearing as a diffuse band from about 
70-77 kDa. (F) C57 Mouse Brain. Mu receptors in mouse brain were ran with a lower 
apparent molecular weight than observed in cell lines, approximately 57-65 kDa. 
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CHO-KOR could also be photolabeled although much less efficiently, resulting in 
a poorer ratio of total to nonspecific labeling. Photolabeled kappa receptors ran with a 
rough peak at the expected 55kDa (not shown) but could be more cleanly observed 
following wheat germ affinity chromatography to isolate glycosylated receptor, running 
as a diffuse band from about 50-57kDa (Figure 46B, Figure 47D).  
 After optimization with highly overexpressing cell lines, we next attempted to 
photoaffinity label opioid receptors in natively expressing tissues. Although nonspecific 
labeling in mouse brain initially prevented visualization of receptors, the addition of an 
immunoaffinity enrichment step dramatically improved detection. CD1 (Figure 46C) or 
C57 (Figure 47F) mouse brain membranes showed a distinctly lower molecular 
molecular weight band for mu receptors, although the this difference in glycosylation 
state between cell lines and even different brain regions has been demonstrated 
previously (Peng Huang et al., 2008). Indeed, even SK-N-BE(2)C membranes, a human 
neuroblastoma cell line which natively expresses mu opioid receptors and splice 
variants, showed a higher molecular weight, much closer to that seen in heterologously 
expressing cell lines (Figure 47E). 
We next attempted to use the technique of blue native PAGE, pioneered by Schägger & 
von Jagow (1991) as a modification of traditional native PAGE to permit estimations of 
molecular weight of proteins with their quaternary interactions unperturbed. 
Photolabeled and immunoprecipitated MOR ran as a single diffuse band at an 
approximately 200kDA in both CHO-MOR and mouse brain membranes (Figure 48). 
Further separation by the addition of a second dimension of electrophoresis showed 
that this band migrated at the expected 70-75 kDa under denaturing and reducing 
conditions. 
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Figure 48. BN-PAGE and 2D BN-PAGE/SDS-PAGE of [125I]-6 Photolabeled Mu Opioid 
Receptors. 
(A) CHO-MOR and Mouse brain membranes were photolabeled and immunoprecipitate 
under nondenaturing conditions before separation by blue native PAGE to yield a single 
diffuse band with an approximate molecular weight of 200kDa. (B) CHO-MOR. A lane 
from a BN-PAGE gel run on photolabeled CHO-MOR membranes was excised from a BN-
PAGE gel, denatured and reduced, and then run in an orthogonal direction on an SDS-
PAGE gel to give 2 dimensions of separation. The 200kDa band from the BN-PAGE gel 
ran at 70-75 kDa, consistent with previous observations for the mu receptor. Results are 
representative figures and have each been replicated by at least 2 independent 
experiments. 
Finally, we achieved the intended purpose of these ligands when an unidentified 
target labeled by [125I]-7 was successfully photolabeled, enriched by 
immunoprecipitation by C-terminal MOR antibody, and visualized following SDS-PAGE 
separation. This is hypothesized to be the truncated 6TM splice variant that is the target 
for IBNtxA and presumably mediates its analgesic actions independently of the 
traditional mu, delta, and kappa opioid receptors.  
115 
 
 
 Figure 49. Photolabeled Target in Triple Knockout Mouse Brain. 
[125I]-7 was used to photolabel the unknown target of IBNtxA in triple knockout mouse 
brain, which was enriched by MOR exon 4 immunoprecipitation. No further tissue from 
this animal could be obtained for a replicate so results should be interpreted with 
caution accordingly. 
Discussion 
 Photoaffinity labeling offers a way to connect the realm of pharmacologically 
defined receptors with their molecular identities. It also permits separation of receptor 
binding on the basis of size or other chromatographic attributes, offering a convenient 
tag for the development of enrichment steps and complex purification schemes. Here, 
we synthesized 2 new photoaffinity labels based on the structure of IBNalA for 
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photolabeling mu and kappa sites, in addition to as-yet unidentified receptors such as 
those observed in triple knockout mouse brain. 
 Both photolabels demonstrated very high affinity for mu and kappa opioid 
receptors, with moderate affinity for delta receptors. The change of the N-substituent 
from an allyl (6) to a propargyl group (7) resulted in a minor 2-fold loss of affinity for mu 
opioid receptors but a >4-fold increase in affinity for the “6TM/E11” target of IBNtxA in 
triple knockout mouse brain, suggesting that this compound in particular might aid in 
the identification of the target and its components. 
 Radioiodinated forms of the drug were synthesized and found to have even 
higher affinity for mu and kappa receptors than predicted based on competition studies. 
Consistent with the extremely high affinity exhibited for mu opioid receptors, the allyl 
photoaffinity label (6) displayed a halflife of dissociation greater than 1 hour at room 
temperature and greater than 4 hours in an ice bath even before covalent coupling of 
the drug to the receptor. This extremely high affinity aided visualization efforts by 
substantially increasing the ratio of total to nonspecific binding. Although substantial 
nonspecific labeling was observed in natively expressing tissues, the addition of an 
immunoprecipitation enrichment step enabled visualization of mu opioid receptors in 
natively expressing neuroblastoma and mouse brain membranes. 
 Interestingly, mu receptors migrated with a markedly different apparent 
molecular weight in mouse brain tissue relative to that observed in both heterologously 
and natively expressing cell lines. This appears to be due to different glycosylation 
patterns, previously reported by the Liu-Chen lab (Peng Huang et al., 2008). In fact, 
Huang et al found different apparent molecular weights for mu receptors labeled by an 
antibody directed at the protein’s C-terminal tail even between brain regions, with 
receptor from the mouse striatum running from 60 – 84 kDa (median 74 kDa), while 
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receptor from mouse thalamus ran with a similar narrower, lower molecular weight as 
we observed, from 58 – 68 kDa (median 63 kDa). Their findings were similar in rat 
striatal and thalamic membranes, suggesting a similar pattern of glycosylation at least 
across rodent species. Thus, it appears that at least on the basis of size, our cell lines 
express a more “striatal-like” glycosylation pattern, while the majority of mu receptors 
in whole mouse brain homogenate appear to express a more “thalamic” pattern, 
consistent with the extremely high density of receptor there. It is unclear what 
ramifications this might have for the use of heterologously-expressing and 
neuroblastoma cell lines as model systems for the study of in vivo opioid pharmacology. 
These results present another reminder that models should never be mistaken for 
nature itself and must always be used with limitations in mind. 
 In addition to separation by SDS-PAGE, we resolved opioid receptors and their 
complexes using non-denaturing blue native gel electrophoresis. On BN-PAGE gels, the 
photolabeled mu receptor species appeared to migrate at a rough molecular weight of 
200 kDa for both CHO-MOR and mouse brain. Several cautions must be addressed 
regarding this rough estimate: first, BN-PAGE is less accurate as an estimate of 
molecular weight than SDS-PAGE. Rather than the denaturing SDS, Coomassie brilliant 
blue G-250 dye is used as a non-denaturing charge shift molecule to ensure that all 
proteins move toward the anode proportionally to the quantity of dye bound to their 
negatively charged residues, approximately proportionally to the protein’s molecular 
weight. However, there may be some nonlinearities introduced by the migration of 
multiprotein complexes especially of multiple oligomeric states, and differing 
detergents. We did not observe a difference in molecular weight for differing detergents 
(MNG-3, DDM, CHAPS); in fact, even protein solubilized in urea and SDS and reduced 
with dithiothreitol ran with the same apparent molecular weight (not shown). These 
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results suggesting that the species observed is may not be a true signaling complex as 
initially hoped, but could reflect the tendency of receptor to form oligomers under non-
denaturing conditions as noted by Simonds et al following purification of delta receptors 
(Simonds et al., 1985). 
 However, although this may make the BN-PAGE less useful from an analytical 
standpoint, this technique can still be used preparatively to provide a second dimension 
of separation for complex mixtures of proteins. This may be especially useful in future 
attempts for unknown receptors for which wheat germ or immunoaffinity enrichment 
steps are not possible or are too low yielding to be of use. 
Finally, we present the first information regarding the target of IBNtxA in triple 
knockout mouse brain. Although a single experiment, the findings were consistent with 
the labeling of a truncated 6TM variant postulated to mediate the actions of IBNtxA and 
offers insights into future studies of this target. 
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Chapter 7: Discussion 
Following their discovery in 2001, truncated 6TM splice variants of the mu opioid 
receptor were considered a curiosity that had little physiological relevance as they failed 
to bind drug on their own and were expressed at low levels relative to traditional mu 
opioid receptors. The demonstration in 2009 that the loss of MOR exon 11-associated 
splice variants resulted in dramatically lower potency of heroin, M6G, and fentanyl, but 
not morphine or methadone, suggested that they might have a more important role 
after all. Here, we have demonstrated a critical role for this set of splice variants in 
mediating the analgesia of multiple classes of drugs, both new and old, opioid and non-
opioid, independent of many dose- and use-limiting side effects. 
The synthesis of the powerful and unique new pain reliever, IBNtxA, conclusively 
implicated 6TM receptors associated with MOR exon 11 in its mechanism of action. 
Importantly, despite a non-selective binding profile, IBNtxA’s analgesia was not 
siginificantly affected by loss of delta, kappa, and exon 1-associated MOR splice variants, 
suggesting that the remaining 6TM receptors were a target for powerful analgesia. 
More importantly still, IBNtxA’s side effect profile showed improved or absent side 
effects classically associated with mu opioid agonists such as morphine. In mice, IBNtxA 
produced no respiratory depression, slow development of tolerance, no apparent 
dependence syndrome, mild constipation (off-target), and most importantly no reward 
in a conditioned place preference assay. In rats, IBNtxA was slightly less potent but 
showed no cross-tolerance with morphine and also did not produce respiratory 
depression. Like behavior, [125I]-IBNtxA binding in rat brain membranes showed similar 
pharmacological trends as in mice although heterogeneity was observed, suggesting the 
possibility of more than one target. Studies of the target’s regional distribution revealed 
highest levels in the thalamus, with binding virtually absent in the cerebellum.  
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Since the studies herein were published, IBNtxA’s efficacy in other pain models 
of neuropathic and inflammatory pain have stoked further interest in the target 
(Wieskopf et al., 2014). Additionally, the recent demonstration by Lu et al that lentiviral 
restoration of mMOR-1G - a 6TM isoform present in the mouse, rat, and human - can 
rescue IBNtxA analgesia in an Exon 1/Exon 11 total mu knockout animal, puts the 
physiological role of 6TM receptors beyond doubt (Lu et al., 2015). 
Next, we re-examined the pharmacology of another historically unusual opioid, 
buprenorphine, which shared many surface similarities with IBNtxA. To our surprise, 
buprenorphine analgesia was totally lost in MOR exon 11 knockout animals, while 
animals lacking MOR exon 1 variants still retained ~40% analgesic efficacy. Lentiviral 
restoration of mMOR-1G expression in MOR Exon 11, but not Exon 1/11 knockout mice, 
rescued buprenorphine analgesia, confirming the involvement of both 6TM and 7TM 
receptor isoforms.  
Side effects present in buprenorphine treated animals such as locomotor 
stimulation and inhibition of gastrointestinal transit were unaffected in MOR exon 11 
knockout animals, suggesting that these undesireable effects have a distinct mechanism 
of action from the target mediating the desired analgesic effects of the drug. In vitro 
assays showed buprenorphine to be an agonist at mu receptors, weak partial agonist or 
neutral antagonist at delta receptors, and inverse agonist at kappa receptors, although 
studies in cell models could not be followed up in brain tissue as no stimulation could be 
observed in brain. Finally, we confirmed that buprenorphine is a perfect biased agonist 
at mu opioid receptors, failing to recruit β-arrestin even at 10µM and potently 
antagonizing the β-arrestin recruitment of DAMGO. 
We next looked at kappa1, alpha2 adrenergic, and cannabinoid type 1 agonist 
analgesia and found that kappa1 and alpha2 adrenergic analgesia was significantly 
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impaired, while cannabinoid analgesia was entirely intact.  As with buprenorphine, 
lentiviral restoration of mMOR-1G in 2 different knockout models rescued analgesic 
efficacy of kappa1 and alpha2 adrenergic agonists. However, as with buprenorphine, side 
effects  – for kappa1 agonists, dysphoria; for alpha2 agonists, sedation as measured by 
depression of spontaneous locomotor activity – were retained in MOR exon 11 
knockout animals, genetically dissociating these effects from the desired analgesic effect 
and suggesting that drugs from these classes might be possible next-generation 
analgesics, devoid of side effects which have thus far limited their more widespread use. 
Finally, 2 new photoaffinity label compounds were synthesized and used to 
photolabel opioid receptors as an attempt at bridging the gap between the world of 
pharmacologically defined receptor targets and the genetic identity of the 
macromolecules binding and mediating the effects of those drugs. These compounds 
are further useful as tags for the quantitation and development of purification schemes 
with known mu opioid receptor splice variants and their associated protein ensembles. 
Protocols were developed for receptors expressed in cell lines and enrichment schemes 
based on immunoaffinity and glycosylation status facilitated the visualization of less 
abundant receptors in natively expressing tissues such as SK-N-BE(2)C and mouse brain 
which both express multiple MOR-1 splice variants. Additionally, we present, to our 
knowledge, the first examination of MOR migration on BN-PAGE and 2D-BN-PAGE/SDS-
PAGE, where the receptor migrated with an apparent molecular weight of 200 kDa, 
much greater than that of its monomeric, glycosylated form. 
Finally, we present initial information regarding the target of IBNtxA in triple 
knockout mouse brain, although further work is needed to confirm and extend these 
observations. Current efforts are ongoing with other triple knockout mouse brain tissue 
as well as other tissues believed to express the target mediating IBNtxA’s effects. 
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The overarching question is, of course, how do these truncated 6TM isoforms 
function, if they do not bind drug on their own? One critical observation is that in 
transfected cell lines, 6TMs appear to be retained in the endoplasmic reticulum rather 
than being expressed at the cell surface (unpublished observations) – however, in MOR 
Exon 1/Exon 11 knockout animals with lentiviral rescue of MOR-1G expression, receptor 
was observed at the cell surface (Lu et al., 2015). As the loss of the normal extracellular 
N-terminal domain from exon 1 results in a loss of all predicted glycosylation sites of the 
receptor, alterations in trafficking are not surprising, as normal chaperones which 
ensure proper folding and transport may require glycosylation. One possibility is that 
some other protein acts as a chaperone in vivo which is absent from the heterologously-
expressing cell lines. If this is true, our current characterization of 6TMs as failing to bind 
drug may even be incorrect. 
Future experiments will also be necessary to determine whether MOR-1G is the 
particular 6TM which is involved or whether other 6TMs, such as MOR-1M and MOR-1N 
which differ at the C-terminus can also rescue analgesic response to IBNtxA, 
buprenorphine, kappa1, and alpha2 adrenergic agonists. 
In conclusion, we have revealed multiple new 6TM-associated targets for the 
development of new pain relievers with superior side effect profiles. These results show 
that the concept of receptor multiplicity is alive and well, and that careful research can 
reveal differences in what previously appeared to be homogenous populations of 
receptors. 
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